#  @endpts Endpoints News Endpoints News posts on X about ipo, novartis, ceo, $abbv the most. They currently have [------] followers and [---] posts still getting attention that total [------] engagements in the last [--] hours. ### Engagements: [------] [#](/creator/twitter::3460109487/interactions)  - [--] Week [------] -29% - [--] Month [-------] +120% - [--] Months [-------] +101% - [--] Year [-------] +203% ### Mentions: [--] [#](/creator/twitter::3460109487/posts_active)  - [--] Month [--] -37% - [--] Months [---] +51% - [--] Year [---] +140% ### Followers: [------] [#](/creator/twitter::3460109487/followers)  - [--] Week [------] +0.12% - [--] Month [------] +0.49% - [--] Months [------] +3% - [--] Year [------] +6.20% ### CreatorRank: [-------] [#](/creator/twitter::3460109487/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [vc firms](/list/vc-firms) [countries](/list/countries) [technology brands](/list/technology-brands) [travel destinations](/list/travel-destinations) [celebrities](/list/celebrities) [exchanges](/list/exchanges) [cryptocurrencies](/list/cryptocurrencies) [us election](/list/us-election) **Social topic influence** [ipo](/topic/ipo), [novartis](/topic/novartis), [ceo](/topic/ceo) #767, [$abbv](/topic/$abbv), [sanofi](/topic/sanofi) #46, [eli lilly](/topic/eli-lilly), [china](/topic/china), [acquisition](/topic/acquisition), [$pfe](/topic/$pfe), [ai](/topic/ai) **Top accounts mentioned or mentioned by** [@johncendpts](/creator/undefined) [@armstrongdrew](/creator/undefined) [@rlcscienceboss](/creator/undefined) [@kylahucik](/creator/undefined) [@andrewedunn](/creator/undefined) [@maxonwifi](/creator/undefined) [@shelbyjliv](/creator/undefined) [@maxgelman](/creator/undefined) [@adrianradocea](/creator/undefined) [@tsrandall](/creator/undefined) [@wearehims](/creator/undefined) [@bylizc](/creator/undefined) [@andybiotech](/creator/undefined) [@cnbc](/creator/undefined) [@astrazenecas](/creator/undefined) [@leileiwuu](/creator/undefined) [@sarepta](/creator/undefined) [@formationbio](/creator/undefined) [@xairathera](/creator/undefined) [@sanofi](/creator/undefined) **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) [AbbVie Inc (ABBV)](/topic/$abbv) [Sanofi (SNY)](/topic/sanofi) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [Pfizer, Inc. (PFE)](/topic/$pfe) [Johnson & Johnson (JNJ)](/topic/$jnj) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Passage Bio, Inc. (PASG)](/topic/passage-bio) [Biogen Inc (BIIB)](/topic/$biib) ### Top Social Posts Top posts by engagements in the last [--] hours "The Carlyle Group shelled out $435 million to acquire more than 90% of Unchained Labs a six-year-old California-based firm from Danish asset manager Novo Holdings and VC firms TPG Biotech and Canaan Partners. https://endpts.com/the-carlyle-group-shells-out-435m-for-controlling-stake-in-vaccine-gene-therapy-services-company/ https://endpts.com/the-carlyle-group-shells-out-435m-for-controlling-stake-in-vaccine-gene-therapy-services-company/" [X Link](https://x.com/endpts/status/1386700128556396549) 2021-04-26T15:14Z 31.1K followers, [--] engagements "The Carlyle Group shelled out $435 million to acquire more than 90% of Unchained Labs a six-year-old California-based firm from Danish asset manager Novo Holdings and VC firms TPG Biotech and Canaan Partners. https://endpts.com/the-carlyle-group-shells-out-435m-for-controlling-stake-in-vaccine-gene-therapy-services-company/ https://endpts.com/the-carlyle-group-shells-out-435m-for-controlling-stake-in-vaccine-gene-therapy-services-company/" [X Link](https://x.com/endpts/status/1386847568341184514) 2021-04-27T01:00Z 31.1K followers, [--] engagements "Partnering up with a group of former collaborators Jo Viney is now guiding the ship at Seismic Therapeutic a Polaris Partners-incubated immunology player that debuted Wednesday with a whopping $101 million A series. https://endpts.com/two-pandion-vets-jump-back-into-the-startup-world-this-time-using-machine-learning-to-build-better-immunology-drugs/ https://endpts.com/two-pandion-vets-jump-back-into-the-startup-world-this-time-using-machine-learning-to-build-better-immunology-drugs/" [X Link](https://x.com/endpts/status/1491402281711030274) 2022-02-09T13:23Z 31.2K followers, [--] engagements "Partnering up with a group of former collaborators Jo Viney is now guiding the ship at Seismic Therapeutic a Polaris Partners-incubated immunology player that debuted Wednesday with a whopping $101 million A series. https://endpts.com/two-pandion-vets-jump-back-into-the-startup-world-this-time-using-machine-learning-to-build-better-immunology-drugs/ https://endpts.com/two-pandion-vets-jump-back-into-the-startup-world-this-time-using-machine-learning-to-build-better-immunology-drugs/" [X Link](https://x.com/endpts/status/1491577658521522176) 2022-02-10T01:00Z 31.2K followers, [--] engagements "Takeda has ended its work with Turnstone Biologics on a solid tumor asset that was in a Phase I/IIa study upending a [----] deal that had $900 million in biobucks on the line. https://endpts.com/takeda-axes-clinical-stage-program-in-turnstone-biologics-collaboration/ https://endpts.com/takeda-axes-clinical-stage-program-in-turnstone-biologics-collaboration/" [X Link](https://x.com/endpts/status/1552689895096946688) 2022-07-28T16:18Z 31.2K followers, [--] engagements "Novo Nordisk snaps up Forma Therapeutics in bid to beef up its sickle cell disease pipeline. https://endpts.com/as-novo-begins-phii-sickle-cell-trial-it-snags-a-later-stage-blood-disorder-drug-in-1-1b-forma-buy/ https://endpts.com/as-novo-begins-phii-sickle-cell-trial-it-snags-a-later-stage-blood-disorder-drug-in-1-1b-forma-buy/" [X Link](https://x.com/endpts/status/1565366369754963976) 2022-09-01T15:50Z 31.1K followers, [--] engagements "After launching Vividion Versant Ventures is back with what it calls a next-gen approach with Belharra Therapeutics. A $50 million Series A will kick things off for the small molecule developer. https://endpts.com/vividion-2-0-ben-cravatt-and-scripps-team-form-a-new-chemoproteomics-biotech/ https://endpts.com/vividion-2-0-ben-cravatt-and-scripps-team-form-a-new-chemoproteomics-biotech/" [X Link](https://x.com/endpts/status/1610687627933491201) 2023-01-04T17:20Z 31.2K followers, [----] engagements "CinCor Pharmas hypertension drug may have failed a Phase II study but that isn't stopping AstraZeneca from betting up to $1.8 billion on CinCor and the drug it licensed from Roche in [----]. https://endpts.com/astrazeneca-bets-up-to-1-8b-on-cincor-and-its-ex-roche-drug-for-hypertension/ https://endpts.com/astrazeneca-bets-up-to-1-8b-on-cincor-and-its-ex-roche-drug-for-hypertension/" [X Link](https://x.com/endpts/status/1612481825246519299) 2023-01-09T16:10Z 31.1K followers, [----] engagements "Gene therapy startup Coda Biotherapeutics has shut down Endpoints has learned. Investors Versant Ventures and MPM Capital declined to share further details about the closure https://endpts.com/biotech-pain-continues-as-versant-mpm-gene-therapy-startup-calls-it-quits/ https://endpts.com/biotech-pain-continues-as-versant-mpm-gene-therapy-startup-calls-it-quits/" [X Link](https://x.com/endpts/status/1633457699294683137) 2023-03-08T13:20Z 31.2K followers, [----] engagements "Out of biotech investor Versant Ventures comes immunology player Santa Ana Bio which recently closed a Series A round and will emerge from stealth later this year https://endpts.com/versants-new-immunology-biotech-santa-ana-bio-snags-series-a-with-gv-tpg-partners-on-board/ https://endpts.com/versants-new-immunology-biotech-santa-ana-bio-snags-series-a-with-gv-tpg-partners-on-board/" [X Link](https://x.com/endpts/status/1634244801557086228) 2023-03-10T17:28Z 31.2K followers, [----] engagements "Codiak BioSciences has ended its 8-year journey filing for bankruptcy as it searches for a bidder "as soon as reasonably practicable" https://endpts.com/codiak-files-for-chapter-11-bankruptcy-as-most-executives-head-for-the-exit/ https://endpts.com/codiak-files-for-chapter-11-bankruptcy-as-most-executives-head-for-the-exit/" [X Link](https://x.com/endpts/status/1640418856530239488) 2023-03-27T18:21Z 31.1K followers, [----] engagements "Biogens $7.3 billion acquisition of Reata Pharmaceuticals its first major deal in more than four years came after a showdown with another potential buyer that saw the acquisition price pushed up from $140 a share to $172.50 $BIIB $RETA https://endpts.com/biogens-7-3b-deal-for-reata-came-after-outbidding-mysterious-party-a/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/biogens-7-3b-deal-for-reata-came-after-outbidding-mysterious-party-a/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1691120129961336832) 2023-08-14T16:10Z 31.1K followers, [----] engagements "Theseus Pharmaceuticals lays off most workers and seeks 'strategic alternatives' after cancer pipeline failure https://endpts.com/theseus-pharmaceuticals-lays-off-most-workers-and-seeks-strategic-alternatives-after-cancer-pipeline-failure/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/theseus-pharmaceuticals-lays-off-most-workers-and-seeks-strategic-alternatives-after-cancer-pipeline-failure/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1724404599430496618) 2023-11-14T12:31Z 31.1K followers, [----] engagements "Last years layoffs were just the start for Vir Biotechnology. https://endpts.com/virs-overhaul-brings-an-end-to-most-virology-work-and-a-beginning-with-cancer/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/virs-overhaul-brings-an-end-to-most-virology-work-and-a-beginning-with-cancer/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1819108597680558251) 2024-08-01T20:31Z 31.2K followers, [----] engagements "Poseida Therapeutics said that [--] of [--] patients (91%) responded to the allogeneic CAR-T therapy its developing with Roche when given a higher dose of a chemo drug called cyclophosphamide than is typical. https://endpts.com/poseida-shares-incremental-phase-1-update-for-roche-partnered-off-the-shelf-car-t/utm_medium=organic_social&utm_campaign=&utm_source=twitter&utm_content=&utm_term= https://endpts.com/poseida-shares-incremental-phase-1-update-for-roche-partnered-off-the-shelf-car-t/utm_medium=organic_social&utm_campaign=&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1841050689138548907) 2024-10-01T09:41Z 31.1K followers, [----] engagements "Alto Neurosciences stock tumbled 60% on Wednesday morning the day after the company said a mid-stage trial for its oral small molecule failed to improve symptoms of major depressive disorder. https://endpts.com/alto-neurosciences-mid-stage-trial-misses-primary-endpoint-in-depression/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/alto-neurosciences-mid-stage-trial-misses-primary-endpoint-in-depression/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1849122115624067556) 2024-10-23T16:14Z 31.2K followers, [----] engagements "A fusion of this years buzziest biotech trends artificial intelligence and obesity drugs is the focus of a new startup backed with $53.5 million from biotech investors Versant Ventures and DCVC. https://endpts.com/exclusive-university-of-toronto-spinout-raises-53-5m-to-create-new-obesity-drugs-with-ai/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/exclusive-university-of-toronto-spinout-raises-53-5m-to-create-new-obesity-drugs-with-ai/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1849468045569171816) 2024-10-24T15:08Z 31.1K followers, [---] engagements "Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday. https://endpts.com/tyra-biosciences-gives-a-first-look-at-its-challenge-to-jjs-targeted-bladder-cancer-drug-balversa/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/tyra-biosciences-gives-a-first-look-at-its-challenge-to-jjs-targeted-bladder-cancer-drug-balversa/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1849839819720941932) 2024-10-25T15:45Z 31.1K followers, [---] engagements "ALK-Abell Pharmaceuticals pays $145M upfront and will get exclusive rights to ARS Pharmaceuticals anaphylaxis drug neffy in all markets except the US Australia New Zealand Japan and China according to a Saturday release. https://endpts.com/alk-abello-licenses-ars-anaphylaxis-nasal-spray-in-certain-markets-for-145m/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/alk-abello-licenses-ars-anaphylaxis-nasal-spray-in-certain-markets-for-145m/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1855984579699466708) 2024-11-11T14:43Z 31.2K followers, [---] engagements "Keros Therapeutics said Thursday morning it has voluntarily halted two of three dosing arms of its experimental drug in a Phase [--] trial due to a safety concern. https://endpts.com/keros-halts-parts-of-phase-2-pah-trial-due-to-safety-stock-tanks-70/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/keros-halts-parts-of-phase-2-pah-trial-due-to-safety-stock-tanks-70/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1867314574707310776) 2024-12-12T21:04Z 31.1K followers, [----] engagements "Pliant Therapeutics pauses enrollment and dosing in a mid-stage study of its lung fibrosis candidate following safety board recommendation. $PLRX was down 58% premarket Monday. https://endpts.com/pliant-shares-plummet-as-phase-2b-lung-fibrosis-study-paused/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/pliant-shares-plummet-as-phase-2b-lung-fibrosis-study-paused/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1888961085614538857) 2025-02-10T14:39Z 31.1K followers, [----] engagements "BeiGene halts Phase [--] trial of TIGIT drug ociperlimab in lung cancer after futility analysis adding to the string of TIGIT setbacks. https://endpts.com/another-tigit-trial-fails-as-beigene-scraps-phase-3-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/another-tigit-trial-fails-as-beigene-scraps-phase-3-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1907888223386231092) 2025-04-03T20:09Z 31.1K followers, [----] engagements "Zealand Pharma named Lilly alum Utpal Singh as its new chief science officer as the company works to leverage a $5.3B obesity deal with Roche into becoming a "generational biotech. https://endpts.com/with-aims-to-become-a-generational-biotech-zealand-pharma-hires-lilly-veteran-as-science-chief/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/with-aims-to-become-a-generational-biotech-zealand-pharma-hires-lilly-veteran-as-science-chief/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1915125653709406270) 2025-04-23T19:28Z 31.1K followers, [----] engagements "ALX Oncologys evorpacept failed two Phase [--] trials in head and neck cancer when combined with Mercks Keytruda. https://endpts.com/alx-oncology-reports-phase-2-failures-for-cd47-drug-combo-with-keytruda/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/alx-oncology-reports-phase-2-failures-for-cd47-drug-combo-with-keytruda/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1915848385917063254) 2025-04-25T19:20Z 31.1K followers, [----] engagements "Vor Biopharma is ending its clinical programs and laying off 95% of staff as the company founded by Siddhartha Mukherjee seeks a buyer or strategic deal. https://endpts.com/blood-cancer-biotech-vor-bio-ends-clinical-work-lays-off-95-of-staff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/blood-cancer-biotech-vor-bio-ends-clinical-work-lays-off-95-of-staff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1920530008461742300) 2025-05-08T17:23Z 31.2K followers, [----] engagements "Lilly is acquiring Verve Therapeutics in a bid to expand its gene editing pipeline for up to $1.3B. https://endpoints.news/eli-lilly-to-buy-gene-editing-biotech-verve-therapeutics-for-up-to-1-3b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/eli-lilly-to-buy-gene-editing-biotech-verve-therapeutics-for-up-to-1-3b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1934978941871112410) 2025-06-17T14:18Z 31.2K followers, [----] engagements "LaNovaMerck's key oncology partnerjust got acquired by Hong-Kong firm Sino Biopharmaceutical for $951M. https://endpoints.news/mercks-partner-lanova-medicines-is-acquired-for-951m-by-sino-biopharmaceutical/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/mercks-partner-lanova-medicines-is-acquired-for-951m-by-sino-biopharmaceutical/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1945212429123629428) 2025-07-15T20:02Z 31.1K followers, [----] engagements "Exclusive: LB Pharmaceuticals is said to be working on IPOfor schizophrenia drug has hired advisors https://endpoints.news/lb-pharmaceuticals-is-said-to-be-working-on-ipo-for-schizophrenia-drugutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lb-pharmaceuticals-is-said-to-be-working-on-ipo-for-schizophrenia-drugutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1958957812908007503) 2025-08-22T18:21Z 31.1K followers, [----] engagements "Novartis plans to pay $12B in cash to buy Avidity Biosciences and its three neuromuscular drugs that could head to the FDA next year. https://endpoints.news/novartis-to-buy-rna-drugmaker-avidity-biosciences-for-12b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-to-buy-rna-drugmaker-avidity-biosciences-for-12b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1982778853639573830) 2025-10-27T11:58Z 31.1K followers, [----] engagements "Flagship and its startups unveiled new deals with GSK Merck KGaA and a major Saudi research institute as the investor and incubator expands its pharma alliances. https://endpoints.news/flagship-and-portfolio-companies-do-deals-with-gsk-merck-kgaa-and-saudi-arabia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/flagship-and-portfolio-companies-do-deals-with-gsk-merck-kgaa-and-saudi-arabia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1991628892554293710) 2025-11-20T22:05Z 31.2K followers, [----] engagements "Kymera's eczema pill shows Dupixent-like efficacy in an early-stage study in what could be a serious challenge to one of todays best-selling medicines. https://endpoints.news/kymeras-pill-looks-competitive-to-dupixent-in-phase-1b-eczema-study/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/kymeras-pill-looks-competitive-to-dupixent-in-phase-1b-eczema-study/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1998038678707593344) 2025-12-08T14:35Z 31.1K followers, [----] engagements "Dyne Therapeutics' Duchenne drug hit its primary endpoint in a pivotal study boosting dystrophin levels and positioning the exon 51skipping therapy for an FDA filing. https://endpoints.news/dyne-says-duchenne-drug-succeeds-in-pivotal-study-heads-to-fda-for-approval/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/dyne-says-duchenne-drug-succeeds-in-pivotal-study-heads-to-fda-for-approval/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1998160291394117772) 2025-12-08T22:38Z 31.1K followers, [----] engagements "Argenx stops late-stage trials of Vyvgart Hytrulo its thyroid eye disease candidate after an interim analysis found the studies were unlikely to succeed. https://endpoints.news/argenx-cans-thyroid-eye-disease-trials-of-vyvgart-hytrulo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/argenx-cans-thyroid-eye-disease-trials-of-vyvgart-hytrulo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2000587851893768413) 2025-12-15T15:24Z 31.2K followers, [----] engagements "Shionogi will acquire one of the only approved ALS drugs for $2.5B. https://endpoints.news/shionogi-will-pay-2-5b-to-acquire-one-of-the-only-approved-als-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/shionogi-will-pay-2-5b-to-acquire-one-of-the-only-approved-als-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2003180586865950883) 2025-12-22T19:07Z 31.1K followers, [----] engagements "Rare disease drugmaker argenx will have a new CEO soon. https://endpoints.news/argenx-to-elevate-massey-to-ceo-as-it-expands-rare-disease-business/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/argenx-to-elevate-massey-to-ceo-as-it-expands-rare-disease-business/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2008292560486244527) 2026-01-05T21:40Z 31.2K followers, [----] engagements "The first biotech acquisition of [----] is here: Amgen is buying Oxford spinout Dark Blue Therapeutics in a deal worth up to $840M adding a preclinical cancer drug to its pipeline. https://endpoints.news/amgen-to-acquire-dark-blue-therapeutics-for-up-to-840m/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/amgen-to-acquire-dark-blue-therapeutics-for-up-to-840m/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2008612260827328814) 2026-01-06T18:50Z 31.2K followers, [----] engagements "Novartis will pay $50M upfront to license a peptide-based radiopharma asset from Chinese-based Zonsen PepLib Biotech. https://endpoints.news/novartis-licenses-radiopharma-asset-from-chinese-biotech-for-50m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-licenses-radiopharma-asset-from-chinese-biotech-for-50m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2011096910182937062) 2026-01-13T15:24Z 31.1K followers, [----] engagements "#JPM26 Day [--] Yesterday we got an update from Amgen on its obesity shot MariTide and insights on the future of biopharma from Novo Nordisk's Mike Doustdar. We're reporting live: https://endpoints.news/jpm26-day-2-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-day-2-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2011103179023499376) 2026-01-13T15:48Z 31.2K followers, [----] engagements "Pfizer is selling its ViiV stake a specialist HIV company it created with GSK to Japan's Shionogi for $2.1B. https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2013729403465830568) 2026-01-20T21:44Z 31.2K followers, [----] engagements "💼In this week's Peer Review: Karin Bok becomes the latest ex-FDA deputy to move to Lilly; also FDA alum Amy Muhlberg takes over as AbbVie's director of US policy; and Angelini Pharma gets a new CEO. Read the full update: https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2014738429901209692) 2026-01-23T16:34Z 31.2K followers, [----] engagements "Sanofi's latest results for its next big immunology hope show mixed results once again. https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2014806617716314143) 2026-01-23T21:05Z 31.1K followers, [----] engagements "Novos Wegovy pill is off to an impressive start: Prescriptions are up 500% in the second week with more than [-----] last week according to BMO Capital Markets. https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2015795620049482076) 2026-01-26T14:35Z 31.1K followers, [----] engagements "Genmab won't enroll any new patients in its early-stage trial of ProfoundBio's cancer candidate. https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2015894460614263166) 2026-01-26T21:07Z 31.2K followers, [----] engagements "Drug pricing fights under the Inflation Reduction Act are piling up at the Supreme Court with Novartis becoming the sixth pharma company to file a challenge as the industrys legal battle reaches a critical stage. https://endpoints.news/ira-drug-pricing-petitions-pile-up-at-the-supreme-court/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ira-drug-pricing-petitions-pile-up-at-the-supreme-court/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2015907841895272897) 2026-01-26T22:00Z 31.1K followers, [----] engagements "Exclusive: Cellares raised $257M to expand its global cell therapy manufacturing footprint as it prepares for a potential IPO as early as the end of [----]. https://endpoints.news/cellares-raises-257m-to-fund-global-expansion-as-it-eyes-2027-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/cellares-raises-257m-to-fund-global-expansion-as-it-eyes-2027-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2016592112645447856) 2026-01-28T19:20Z 31.1K followers, [----] engagements "Sanofi says it has up to 15B to spend on deals this year with M&A and R&D key to easing the looming patent cliff for blockbuster Dupixent. https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2016912963915977029) 2026-01-29T16:34Z 31.2K followers, [----] engagements "AstraZeneca is committing $15B through [----] to expand R&D and manufacturing in China as the country cements its role as a global hub for drug development. https://endpoints.news/astrazeneca-makes-15b-bet-on-china-to-expand-manufacturing-and-rd/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-makes-15b-bet-on-china-to-expand-manufacturing-and-rd/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2017003236708753547) 2026-01-29T22:33Z 31.1K followers, [----] engagements "AstraZeneca is paying $1.2B upfront for CSPC's long-acting obesity drugs part of its commitment to invest $15B in China by [----]. https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2017247397588427004) 2026-01-30T14:43Z 31.2K followers, [----] engagements "One cancer drug steps back and obesity asset steps forward as Pfizer reports earnings. https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2018701657631031301) 2026-02-03T15:02Z 31.1K followers, [----] engagements "Two Stanford PhDs created an AI system for scientists last year; today they're launching their startup after raising $13.5M. World meet Phylo. https://endpoints.news/menlo-and-a16z-back-ai-scientist-startup-phylo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/menlo-and-a16z-back-ai-scientist-startup-phylo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2018731961041158549) 2026-02-03T17:03Z 31.1K followers, [----] engagements "AccurEdit raises $75M in a Series A to advance its CRISPR pipeline one of the largest rounds in the Chinese gene editing club. https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2018781744892358706) 2026-02-03T20:20Z 31.1K followers, [----] engagements "Novo Nordisk forecast a sales drop of at least 5% in [----] citing MFN pricing pressure sending its shares down more than 14% and dragging other obesity stocks with it. https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2018799328765399273) 2026-02-03T21:30Z 31.1K followers, [----] engagements "The rare pediatric PRV program is back. A government funding bill reauthorized the FDAs ability to issue pediatric priority review vouchers through [----] reviving a key incentive for rare disease drug development. https://endpoints.news/rare-pediatric-prv-program-reauthorized-until-2029-via-government-funding-law/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/rare-pediatric-prv-program-reauthorized-until-2029-via-government-funding-law/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019153133788885104) 2026-02-04T20:56Z 31.1K followers, [----] engagements "Angitia raised a $130M Series D to advance three clinical-stage biologics for musculoskeletal diseases continuing momentum for the US-China biotech as it eyes a potential IPO. https://endpoints.news/angitia-gets-130m-series-d-for-pipeline-of-musculoskeletal-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/angitia-gets-130m-series-d-for-pipeline-of-musculoskeletal-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019476705732137141) 2026-02-05T18:22Z 31.1K followers, [---] engagements "Flagship-backed Generate:Biomedicines has filed for an IPO just days after dosing its first Phase [--] patient setting up a major test for the AI biotech sector. https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019490003340886155) 2026-02-05T19:15Z 31.1K followers, [----] engagements "Eikons IPO may be the biggest biotech debut in two years but the sharp valuation reset shows how tough the public markets remain for big-name big-money biotechs and what the next wave could face. https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019498208687222868) 2026-02-05T19:47Z 31.1K followers, [----] engagements "Priovant Therapeutics heads to Phase [--] trial for its immune skin disease candidate after "landmark transformative" success in Phase [--]. https://endpoints.news/roivant-spinout-priovant-touts-phase-2-brepocitinib-data-in-cutaneous-sarcoidosis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/roivant-spinout-priovant-touts-phase-2-brepocitinib-data-in-cutaneous-sarcoidosis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019776289536717077) 2026-02-06T14:12Z 31.2K followers, [----] engagements "🚨 US calls for investigation of @wearehims over GLP-1 drugs threatening 'decisive steps' Breaking news from @ShelbyJLiv https://endpoints.news/us-calls-for-doj-investigation-of-hims-over-glp-1-drugs/ https://endpoints.news/us-calls-for-doj-investigation-of-hims-over-glp-1-drugs/" [X Link](https://x.com/endpts/status/2019912272773005574) 2026-02-06T23:13Z 31.2K followers, [----] engagements "Adlai Nortye a Hangzhou China-based biotech with operations in North Brunswick NJ has applied to trade on the Hong Kong Exchange just days after scoring a fundraising round to pursue its license-heavy business model according to a Tuesday filing. https://endpts.com/a-novartis-castoff-with-a-troubled-past-headlines-chinese-biotechs-hong-kong-ipo-quest/ https://endpts.com/a-novartis-castoff-with-a-troubled-past-headlines-chinese-biotechs-hong-kong-ipo-quest/" [X Link](https://x.com/endpts/status/1417826239247790082) 2021-07-21T12:38Z 31.2K followers, [--] engagements "A month and a half after a short sell attack nearly brought Ginkgo Bioworks newly public shares to its knees the company took its largest step yet toward clearing its name. But it also revealed its currently the target of a Department of Justice probe. https://endpts.com/as-ginkgo-looks-to-clear-its-name-the-feds-have-come-sniffing-around-on-the-heels-of-short-sell-report/ https://endpts.com/as-ginkgo-looks-to-clear-its-name-the-feds-have-come-sniffing-around-on-the-heels-of-short-sell-report/" [X Link](https://x.com/anyuser/status/1460281097062084608) 2021-11-15T16:18Z 31.2K followers, [--] engagements "When Sorrento first unveiled plans to take its subsidiary Scilex public by merging with the blank check company Vickers Vantage Corp I last December it was clinging to the tail-end of a fading SPAC boom in healthcare. But it's still marching ahead. https://endpts.com/going-against-the-current-sorrento-spins-out-pain-focused-subsidiary-in-140m-spac-deal/ https://endpts.com/going-against-the-current-sorrento-spins-out-pain-focused-subsidiary-in-140m-spac-deal/" [X Link](https://x.com/endpts/status/1504837388056543240) 2022-03-18T15:09Z 31.2K followers, [--] engagements "When Sorrento first unveiled plans to take its subsidiary Scilex public by merging with the blank check company Vickers Vantage Corp I last December it was clinging to the tail-end of a fading SPAC boom in healthcare. But it's still marching ahead. https://endpts.com/going-against-the-current-sorrento-spins-out-pain-focused-subsidiary-in-140m-spac-deal/ https://endpts.com/going-against-the-current-sorrento-spins-out-pain-focused-subsidiary-in-140m-spac-deal/" [X Link](https://x.com/endpts/status/1505620187550208005) 2022-03-20T19:00Z 31.2K followers, [--] engagements "Kelonia Therapeutics backed by VCs such as Horizons Ventures and Venrock officially launched Thursday after being in stealth for a little over a year and has a bit of a cash stash thanks to $50 million from a Series A. https://endpts.com/gene-therapy-outfit-emerges-from-stealth-with-big-ambitions-first-stop-car-t/ https://endpts.com/gene-therapy-outfit-emerges-from-stealth-with-big-ambitions-first-stop-car-t/" [X Link](https://x.com/endpts/status/1519650133536763904) 2022-04-28T12:10Z 31.2K followers, [--] engagements "The reasoning for withdrawing its IPO desires Artiva Biotherapeutics had a different big plan to share one that couldnt be done under the constraints of having an S-1 on file with the SEC. https://endpts.com/artiva-after-pulling-ipo-plans-partners-with-affimed-to-speed-up-nk-cell-therapy-combo/ https://endpts.com/artiva-after-pulling-ipo-plans-partners-with-affimed-to-speed-up-nk-cell-therapy-combo/" [X Link](https://x.com/endpts/status/1588196805564514305) 2022-11-03T15:50Z 31.2K followers, [--] engagements "Kronos Bio axes nearly one-fifth of staff to preserve cash for two cancer programs https://endpts.com/kronos-bio-axes-nearly-one-fifth-of-staff-to-preserve-cash-for-two-cancer-programs/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/kronos-bio-axes-nearly-one-fifth-of-staff-to-preserve-cash-for-two-cancer-programs/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1720421327448731674) 2023-11-03T12:43Z 31.2K followers, [----] engagements "Boundless Bio a cancer biotech with two different oral small molecules in Phase [--] testing eyes about $88.4 million in net proceeds from its proposed IPO. https://endpts.com/boundless-bio-seeks-88m-in-ipo-as-it-runs-two-ph1-cancer-trials/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/boundless-bio-seeks-88m-in-ipo-as-it-runs-two-ph1-cancer-trials/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1770837756257730697) 2024-03-21T15:39Z 31.2K followers, [----] engagements "LENZ Therapeutics plans to seek FDA approval for its investigational eye drops for presbyopia setting up the drug to compete against AbbVies Vuity and Orasis Pharmaceuticals Qlosi. https://endpts.com/lenz-therapeutics-plans-nda-submission-this-year-for-farsightedness-eye-drops/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/lenz-therapeutics-plans-nda-submission-this-year-for-farsightedness-eye-drops/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1775557772391645511) 2024-04-03T16:15Z 31.2K followers, [----] engagements "Regulatory RNA startup CAMP4 Therapeutics has inked another collaboration deal as it prepares for an initial public offering. https://endpts.com/camp4-preparing-for-ipo-announces-partnership-with-biomarin/utm_medium=organic_social&utm_campaign=&utm_source=twitter&utm_content=&utm_term= https://endpts.com/camp4-preparing-for-ipo-announces-partnership-with-biomarin/utm_medium=organic_social&utm_campaign=&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1841145304709472270) 2024-10-01T15:57Z 31.2K followers, [---] engagements "Adi Hoess describes himself as someone who likes to build companies focused on challenging technologies. Its fitting then that after spending more than a decade as CEO of German biotech Affimed hes moving to nanomedicine company ViaNautis Bio. https://endpts.com/exclusive-ex-affimed-ceo-heads-to-uk-nanomedicine-biotech-jami-rubin-leaves-boundless-bio-after-ipo/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1847367452327395691) 2024-10-18T20:01Z 31.2K followers, [----] engagements "Apogee Therapeutics is headed toward a Dupixent face-off next year as it looks to become the next generational biotech writes @ky_lahucik https://endpts.com/apogee-targets-dupixent-head-to-head-next-year-as-it-outlines-broad-pipeline-plans/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/apogee-targets-dupixent-head-to-head-next-year-as-it-outlines-broad-pipeline-plans/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1863566647585345667) 2024-12-02T12:51Z 31.2K followers, [----] engagements "Bristol Myers is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with Century Therapeutics for natural killer cell and T cell-based cancer treatments as part of its plans to save $1.5bn. https://endpts.com/bristol-myers-drops-cell-therapy-pacts-with-immatics-century-as-part-of-portfolio-review/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1868705125495456200) 2024-12-16T17:09Z 31.2K followers, [----] engagements "Sionna Therapeutics and Odyssey Therapeutics are the latest biotechs to try to go public filing for IPOs at the end of #JPM25 week. https://endpts.com/sionna-and-odyssey-end-jpm-week-with-ipo-filings/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/sionna-and-odyssey-end-jpm-week-with-ipo-filings/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1881695397997101297) 2025-01-21T13:28Z 31.2K followers, [----] engagements "ALX Oncology is eyeing a potential accelerated approval pathway for its CD47-targeting drug in gastric cancer after reporting more data from a Phase [--] trial. https://endpts.com/alx-oncology-to-make-case-for-accelerated-approval-with-evorpacept-in-gastric-cancer/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/alx-oncology-to-make-case-for-accelerated-approval-with-evorpacept-in-gastric-cancer/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1882868527062974553) 2025-01-24T19:10Z 31.2K followers, [----] engagements "Omega Therapeutics expects filing for bankruptcy within the next week just under a year after entering in an obesity partnership with Novo. https://endpts.com/omega-therapeutics-nears-bankruptcy-filing-lays-off-workers/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/omega-therapeutics-nears-bankruptcy-filing-lays-off-workers/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1886808543426158864) 2025-02-04T16:06Z 31.2K followers, [----] engagements "Concentra acquires Cargo Therapeutics marking its fifth deal this year. https://endpoints.news/shell-company-concentra-has-found-its-rhythm-with-cargo-therapeutics-as-its-latest-buyout-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/shell-company-concentra-has-found-its-rhythm-with-cargo-therapeutics-as-its-latest-buyout-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1942656863214137488) 2025-07-08T18:47Z 31.2K followers, [----] engagements "Century Therapeutics is cutting half of its workforce by the end of the third quarter. https://endpoints.news/century-therapeutics-lays-off-half-of-its-staff-cfo-departs-as-it-narrows-priorities/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/century-therapeutics-lays-off-half-of-its-staff-cfo-departs-as-it-narrows-priorities/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1943772707293725124) 2025-07-11T20:41Z 31.2K followers, [----] engagements "XOMA is acquiring HilleVax and Lava Therapeutics as the biotech royalty market heats up with deal sizes growing in [----] despite a slower pace. OrbiMed also raised $1.86B for a new royalty fund. https://endpoints.news/royalty-market-accelerates-as-xoma-acquires-two-biotechs-and-orbimed-bags-another-fund/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/royalty-market-accelerates-as-xoma-acquires-two-biotechs-and-orbimed-bags-another-fund/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1952427532419989839) 2025-08-04T17:52Z 31.2K followers, [----] engagements "IO Biotech is seeking FDA approval after its cancer vaccine narrowly failed a pivotal study for skin cancer. https://endpoints.news/io-biotech-to-seek-fda-filing-even-though-cancer-vaccine-narrowly-fails-pivotal-skin-cancer-study/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/io-biotech-to-seek-fda-filing-even-though-cancer-vaccine-narrowly-fails-pivotal-skin-cancer-study/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1954989092074041734) 2025-08-11T19:31Z 31.2K followers, [----] engagements "Novartis said it's buying Tourmaline Bio for $1.4B with the intent to gain a new heart drug. https://endpoints.news/novartis-to-spend-1-4b-on-tourmaline-bio-gaining-new-heart-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-to-spend-1-4b-on-tourmaline-bio-gaining-new-heart-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1965434672864973162) 2025-09-09T15:18Z 31.2K followers, [---] engagements "Tourmaline Bio's $1.4B buyout this month attracted a small bidding war new documents show with the final sale coming in $20 per share above the starting point. https://endpoints.news/tourmaline-attracted-small-bidding-war-before-1-4b-sale-to-novartis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/tourmaline-attracted-small-bidding-war-before-1-4b-sale-to-novartis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1972741375528685981) 2025-09-29T19:12Z 31.2K followers, [----] engagements "Tvardi's shares $TVRD crashed this morning after the company reported a mid-stage trial failure for its STAT3 candidate. https://endpoints.news/tvardis-stock-crashes-as-stat3-drug-fails-phase-2-after-dropouts-from-side-effects/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/tvardis-stock-crashes-as-stat3-drug-fails-phase-2-after-dropouts-from-side-effects/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1977793337353744848) 2025-10-13T17:47Z 31.2K followers, [----] engagements "Join us online today at [--] AM ET: Health tech data sharing and AI are redefining care under the Trump Administration. Hear from Hinge Healths Daniel Perez and experts at URA Oracle and the Digital Medicine Society. Don't miss it register now. https://events.endpoints.news/healthtech2025/9505283ref=twitter https://events.endpoints.news/healthtech2025/9505283ref=twitter" [X Link](https://x.com/endpts/status/1986451367980863554) 2025-11-06T15:11Z 31.2K followers, [----] engagements "Hinge Health CEO Daniel Perez spent two years prepping for an IPO then went live on the S&Ps worst day of the year. Heres how he pulled it off. https://endpoints.news/how-hinge-health-pulled-off-its-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/how-hinge-health-pulled-off-its-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1988347063386398877) 2025-11-11T20:44Z 31.2K followers, [----] engagements "After a year of major deals the PD-(L)1xVEGF bispecific race is heating up with Summit Pfizer-3SBio and BMS-BioNTech vying to shape cancers next frontier. https://endpoints.news/heres-how-the-pd-l1xvegf-bispecific-race-is-looking-so-far/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/heres-how-the-pd-l1xvegf-bispecific-race-is-looking-so-far/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1988690072162693424) 2025-11-12T19:27Z 31.2K followers, [----] engagements "Zealand Pharma paused development of its GLP-1/GLP-2 obesity drug dapiglutide to focus on higher-priority programs. https://endpoints.news/zealand-pauses-development-of-glp-1-glp-2-obesity-candidate/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/zealand-pauses-development-of-glp-1-glp-2-obesity-candidate/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1989032419127902529) 2025-11-13T18:07Z 31.2K followers, [----] engagements "Structure Therapeutics GLP-1 cut weight by a placebo-adjusted average of 11.3% in Phase [--] stacking up with oral contenders from Novo and Lilly and setting up Phase [--] plans. https://endpoints.news/structure-therapeutics-obesity-pill-stacks-up-with-novo-and-lilly-ascletis-also-reports-early-results/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/structure-therapeutics-obesity-pill-stacks-up-with-novo-and-lilly-ascletis-also-reports-early-results/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1998137964787089913) 2025-12-08T21:09Z 31.2K followers, [----] engagements "AbbVie struck another China deal paying $100M upfront for Zelgens DLL3-targeted T cell engager and adding up to $1.075B in potential milestones. https://endpoints.news/abbvie-does-t-cell-engager-deal-in-china-for-zelgens-dll3-targeted-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/abbvie-does-t-cell-engager-deal-in-china-for-zelgens-dll3-targeted-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2007145036253904911) 2026-01-02T17:40Z 31.2K followers, [----] engagements "#JPM26 day 3: As the conference winds down were tracking updates from WuXi AppTec and AbbVie plus reactions from Lillys CEO who says hes unfazed by rising competition. Follow along for the latest from San Francisco. https://endpoints.news/jpm26-day-3-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-day-3-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2011471665151021376) 2026-01-14T16:13Z 31.2K followers, [----] engagements "#JPM26 takeaway GLP-1s are hot. Every time you mention GLP-1 Im going to charge you $5. Im going to donate it to I dont know an injured Canadian seals fund or something like that" Sandoz CEO Richard Saynor said. https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2012209181336523027) 2026-01-16T17:03Z 31.2K followers, [----] engagements "Sanofi's rare disease drugs gets mixed results in late-stage trials with a win in Gaucher diseases and a loss in Fabry disease. https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2018310184741786004) 2026-02-02T13:07Z 31.2K followers, [----] engagements "Pfizer announced this morning that patients taking the Metsera-originated obesity injection lost 10.5% of their body weight in six months. But it wasn't enough to meet sky-high hopes. https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2018701326834638945) 2026-02-03T15:01Z 31.2K followers, [----] engagements "The FDA has handed a CRL to AstraZeneca for its self-injectable candidate for Lupus one month after it was approved in Europe. https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2018719611429015962) 2026-02-03T16:13Z 31.2K followers, [----] engagements "Eli Lilly beat sales expectations and is projecting major growth in [----] fueled by its tirzepatide franchise a sharp contrast to rival Novo Nordisks forecasted decline. https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019084111202173420) 2026-02-04T16:22Z 31.2K followers, [---] engagements "Novartis expects generics to cut about $4B from [----] sales with Entresto taking a sharp hit in Q4 as competition ramps up. https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019094876063695105) 2026-02-04T17:05Z 31.2K followers, [----] engagements "Veradermics pulled off a $256M upsized IPO for its oral version of Rogaine a debut that points to renewed investor appetite for biotech listings. https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019139235564187727) 2026-02-04T20:01Z 31.2K followers, 38.1K engagements "🎙Post-Hoc Live today at 12pm ET: The big showdown between drugmakers and compounders is finally here.🥊 Join @ArmstrongDrew and @ShelbyJLiv as they dissect Hims' decision to sell low-cost GLP-1s. 🥊 https://endpoints.news/post-hoc-live-analyzing-the-novo-vs-hims-glp-1-showdown/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/post-hoc-live-analyzing-the-novo-vs-hims-glp-1-showdown/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2019802031100231851) 2026-02-06T15:55Z 31.2K followers, [---] engagements "🚨 Novo Nordisk is suing Hims for patent infringement of its semaglutide in both pill and injectable form. Last week Hims announced a compounded version of Wegovy pill (Novo's GLP-1) before reversing course on Saturday. https://endpoints.news/novo-nordisk-sues-hims-over-wegovy-patent-infringement-considers-seeking-hundreds-of-millions-in-damages/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2020857504574415046) 2026-02-09T13:49Z 31.2K followers, [----] engagements "Lilly is buying Orna for $2.4B the largest buyout of an in vivo cell therapy company to date. https://endpoints.news/lilly-joins-in-vivo-car-t-sprint-with-2-4b-orna-acquisition/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lilly-joins-in-vivo-car-t-sprint-with-2-4b-orna-acquisition/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2020923701404078588) 2026-02-09T18:12Z 31.2K followers, [---] engagements "Is AstraZeneca on track to meet its $80B revenue target https://endpoints.news/is-astrazeneca-on-track-to-meet-its-80b-revenue-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/is-astrazeneca-on-track-to-meet-its-80b-revenue-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2021290867424657840) 2026-02-10T18:31Z 31.2K followers, [---] engagements "Money keeps flowing for private obesity and MASH developers. Cascade is the latest biotech to receive a pool of capital about $72M. https://endpoints.news/shanghais-cascade-gets-72m-to-pursue-mash-obesity-and-diabetes-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/shanghais-cascade-gets-72m-to-pursue-mash-obesity-and-diabetes-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2021320644252549330) 2026-02-10T20:29Z 31.2K followers, [----] engagements "Clinical trials are getting more complex and more expensive with redundant standards and mounting data demands driving up costs just as China moves faster and cheaper. Endpoints @MaxGelman dives into the problem in todays Endpoints in Focus. https://endpoints.news/how-a-closet-full-of-ekg-machines-illustrates-pharmas-clinical-trial-cost-problem/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/anyuser/status/2021681135323902241) 2026-02-11T20:21Z 31.2K followers, [----] engagements "Serial entrepreneur Tillman Gerngross antibody play Adagio raced into a pivotal trial for its lead #Covid19 drug when it was less than a year old. Now crossover investors are rolling up the Brinks truck and that could spell an IPO in the offing. https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/ https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/" [X Link](https://x.com/endpts/status/1384166542821138443) 2021-04-19T15:26Z 31.2K followers, [--] engagements "Serial entrepreneur Tillman Gerngross antibody play Adagio raced into a pivotal trial for its lead #Covid19 drug when it was less than a year old. Now crossover investors are rolling up the Brinks truck and that could spell an IPO in the offing. https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/ https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/" [X Link](https://x.com/endpts/status/1384242902725906440) 2021-04-19T20:30Z 31.2K followers, [--] engagements "Tillman Gerngross certainly wasnt the first to tackle #Covid19 antibodies but he has reason to believe he and his team at Adagio could be the best. Now were getting a first peek at human preventative data for Adagios lead antibody. https://endpts.com/adagio-offers-first-peek-at-covid-19-antibody-data-with-preventative-numbers-that-may-rival-mrna-vaccines/ https://endpts.com/adagio-offers-first-peek-at-covid-19-antibody-data-with-preventative-numbers-that-may-rival-mrna-vaccines/" [X Link](https://x.com/endpts/status/1389919974341419010) 2021-05-05T12:28Z 31.2K followers, [--] engagements "Bioregnum: Tillman Gerngross is betting well over $500M that the pandemic will never really end. Heres the IPO pitch https://endpts.com/tillman-gerngross-is-betting-well-over-500m-that-the-pandemic-will-never-really-end-heres-the-ipo-pitch/ https://endpts.com/tillman-gerngross-is-betting-well-over-500m-that-the-pandemic-will-never-really-end-heres-the-ipo-pitch/" [X Link](https://x.com/endpts/status/1417097706401587200) 2021-07-19T12:23Z 31.2K followers, [--] engagements "Bioregnum: Tillman Gerngross is betting well over $500M that the pandemic will never really end. Heres the IPO pitch https://endpts.com/tillman-gerngross-is-betting-well-over-500m-that-the-pandemic-will-never-really-end-heres-the-ipo-pitch/ https://endpts.com/tillman-gerngross-is-betting-well-over-500m-that-the-pandemic-will-never-really-end-heres-the-ipo-pitch/" [X Link](https://x.com/endpts/status/1417273051255775235) 2021-07-20T00:00Z 31.2K followers, [--] engagements "In this week's Peer Review: Back in May Passage Bio CFO Richard Morris and CMO Gary Romano left within days of each other but this week the gene therapy player has found their replacements along with a chief commercial officer. https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/ https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/" [X Link](https://x.com/endpts/status/1418584356013105163) 2021-07-23T14:50Z 31.2K followers, [--] engagements "In this week's Peer Review: Back in May Passage Bio CFO Richard Morris and CMO Gary Romano left within days of each other but this week the gene therapy player has found their replacements along with a chief commercial officer. https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/ https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/" [X Link](https://x.com/endpts/status/1418654651210027009) 2021-07-23T19:30Z 31.2K followers, [--] engagements "In this week's Peer Review: Back in May Passage Bio CFO Richard Morris and CMO Gary Romano left within days of each other but this week the gene therapy player has found their replacements along with a chief commercial officer. https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/ https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/" [X Link](https://x.com/endpts/status/1419326579105169412) 2021-07-25T16:00Z 31.2K followers, [--] engagements "In today's #Covid19 roundup: Antibody legend Tillman Gerngross has inked a deal to develop Adagios lead candidate for the treatment and prevention of Covid-19 in southern Asia. https://endpts.com/covid-19-roundup-tillman-gerngross-inks-deal-to-bring-antibody-candidate-to-india-at-fdas-request-mrna-vaccine-makers-will-expand-trials-for-children-ages-5-11/ https://endpts.com/covid-19-roundup-tillman-gerngross-inks-deal-to-bring-antibody-candidate-to-india-at-fdas-request-mrna-vaccine-makers-will-expand-trials-for-children-ages-5-11/" [X Link](https://x.com/endpts/status/1420029482656747526) 2021-07-27T14:33Z 31.2K followers, [--] engagements "The biotech industry was set to end this week with another two major public debuts. The first company Tillman Gerngross antibody startup Adagio Therapeutics priced a $300 million-plus IPO. But the second WCG Clinical fell through on its IPO plans. https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/ https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/" [X Link](https://x.com/endpts/status/1423665382133583873) 2021-08-06T15:20Z 31.2K followers, [--] engagements "The biotech industry was set to end this week with another two major public debuts. The first company Tillman Gerngross antibody startup Adagio Therapeutics priced a $300 million-plus IPO. But the second WCG Clinical fell through on its IPO plans. https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/ https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/" [X Link](https://x.com/endpts/status/1424098020325474308) 2021-08-07T20:00Z 31.2K followers, [--] engagements "The biotech industry was set to end this week with another two major public debuts. The first company Tillman Gerngross antibody startup Adagio Therapeutics priced a $300 million-plus IPO. But the second WCG Clinical fell through on its IPO plans. https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/ https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/" [X Link](https://x.com/endpts/status/1424354708865519618) 2021-08-08T13:00Z 31.2K followers, [--] engagements "Hot off of his biotech unicorn landing on the Nasdaq another project from the lab of Dartmouth College engineering professor Tillman Gerngross has made news as its been acquired by Repligen. https://endpts.com/tillman-gerngross-project-out-of-dartmouth-college-acquired-by-repligen/ https://endpts.com/tillman-gerngross-project-out-of-dartmouth-college-acquired-by-repligen/" [X Link](https://x.com/endpts/status/1441380954065358848) 2021-09-24T12:36Z 31.2K followers, [--] engagements "Avitide will now be owned by Repligen the company announced last Thursday in a move made to boost its proteins business. https://endpts.com/tillman-gerngross-project-out-of-dartmouth-college-acquired-by-repligen/ https://endpts.com/tillman-gerngross-project-out-of-dartmouth-college-acquired-by-repligen/" [X Link](https://x.com/endpts/status/1443697169706348549) 2021-09-30T22:00Z 31.2K followers, [--] engagements "Tillman Gerngross the rarely shy antibody expert has been warning for over a year that the virus behind #Covid19 would likely continue to mutate. As the world scrambles to face a new variant Omicron that prediction looks particularly prescient. https://endpts.com/tillman-gerngross-on-omicron-it-is-a-grim-situation-were-going-to-see-a-significant-drop-in-vaccine-efficacy/ https://endpts.com/tillman-gerngross-on-omicron-it-is-a-grim-situation-were-going-to-see-a-significant-drop-in-vaccine-efficacy/" [X Link](https://x.com/endpts/status/1465299905694642185) 2021-11-29T12:41Z 31.2K followers, [--] engagements "Tillman Gerngross the rarely shy antibody expert has been warning for over a year that the virus behind #Covid19 would likely continue to mutate. As the world scrambles to face a new variant Omicron that prediction looks particularly prescient. https://endpts.com/tillman-gerngross-on-omicron-it-is-a-grim-situation-were-going-to-see-a-significant-drop-in-vaccine-efficacy/ https://endpts.com/tillman-gerngross-on-omicron-it-is-a-grim-situation-were-going-to-see-a-significant-drop-in-vaccine-efficacy/" [X Link](https://x.com/endpts/status/1465425341594288135) 2021-11-29T21:00Z 31.2K followers, [--] engagements "When Harvard professor Leonard Zon told serial entrepreneur Tillman Gerngross he had a question Gerngross replied: The answer is antibodies. Whats the question Roughly three years later their company Amagma Therapeutics is emerging from stealth mode. https://endpts.com/antibody-legend-tillman-gerngross-introduces-his-latest-company-with-an-innovent-deal-already-lined-up/ https://endpts.com/antibody-legend-tillman-gerngross-introduces-his-latest-company-with-an-innovent-deal-already-lined-up/" [X Link](https://x.com/endpts/status/1483470722970402817) 2022-01-18T16:05Z 31.2K followers, [--] engagements "When Harvard professor Leonard Zon told serial entrepreneur Tillman Gerngross he had a question Gerngross replied: The answer is antibodies. Whats the question Roughly three years later their company Amagma Therapeutics is emerging from stealth mode. https://endpts.com/antibody-legend-tillman-gerngross-introduces-his-latest-company-with-an-innovent-deal-already-lined-up/ https://endpts.com/antibody-legend-tillman-gerngross-introduces-his-latest-company-with-an-innovent-deal-already-lined-up/" [X Link](https://x.com/endpts/status/1483582474424709124) 2022-01-18T23:30Z 31.2K followers, [--] engagements "On Wednesday evening Adagio put out a release saying that founding CEO Tillman Gerngross a high profile figure in the antibody world had resigned confirming an earlier SEC filing that he had agreed to leave. https://endpts.com/tillman-gerngross-makes-it-official-hes-out-as-ceo-as-troubled-adagio-vows-to-soldier-on/ https://endpts.com/tillman-gerngross-makes-it-official-hes-out-as-ceo-as-troubled-adagio-vows-to-soldier-on/" [X Link](https://x.com/endpts/status/1496842464199512069) 2022-02-24T13:40Z 31.2K followers, [--] engagements "Peer Review: As market volatility sweeps through the landscape CEO changes are ramping up and topping the list is Tillman Gerngross a force in the antibody space who hitched his wagon to finding another Covid-19 solution by co-founding Adagio. https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/ https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/" [X Link](https://x.com/endpts/status/1497198832463060996) 2022-02-25T13:16Z 31.2K followers, [--] engagements "Peer Review: As market volatility sweeps through the landscape CEO changes are ramping up and topping the list is Tillman Gerngross a force in the antibody space who hitched his wagon to finding another Covid-19 solution by co-founding Adagio. https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/ https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/" [X Link](https://x.com/endpts/status/1497723158085849091) 2022-02-27T00:00Z 31.2K followers, [--] engagements "Peer Review: As market volatility sweeps through the landscape CEO changes are ramping up and topping the list is Tillman Gerngross a force in the antibody space who hitched his wagon to finding another Covid-19 solution by co-founding Adagio. https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/ https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/" [X Link](https://x.com/endpts/status/1497979848777625600) 2022-02-27T17:00Z 31.2K followers, [--] engagements "A new competitor has emerged from stealth to challenge Vertex in cystic fibrosis. Sionna Therapeutics a Sanofi Genzyme spinout announced its launch with $111 million in Series B financing led by OrbiMed. https://endpts.com/orbimed-backed-biotech-looks-to-challenge-vertex-in-cystic-fibrosis-by-drugging-the-undruggable/ https://endpts.com/orbimed-backed-biotech-looks-to-challenge-vertex-in-cystic-fibrosis-by-drugging-the-undruggable/" [X Link](https://x.com/endpts/status/1516506927726923779) 2022-04-19T20:00Z 31.2K followers, [--] engagements "California biotech Applied Molecular Transport said today it will halt all R&D and seek 'strategic alternatives' https://endpts.com/applied-molecular-transport-prepares-to-close-up-shop-as-it-pauses-rd-replaces-ceo-lays-off-57/ https://endpts.com/applied-molecular-transport-prepares-to-close-up-shop-as-it-pauses-rd-replaces-ceo-lays-off-57/" [X Link](https://x.com/endpts/status/1640703770169417728) 2023-03-28T13:13Z 31.2K followers, [----] engagements "Generation Bio to lay off [--] employees in a difficult year for non-viral gene therapy biotechs https://endpts.com/generation-bio-to-lay-off-68-employees-in-a-difficult-year-for-non-viral-gene-therapy-biotechs/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/generation-bio-to-lay-off-68-employees-in-a-difficult-year-for-non-viral-gene-therapy-biotechs/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1729918970768011489) 2023-11-29T17:43Z 31.2K followers, [----] engagements "Structure Therapeutics oral GLP-1 hit all endpoints in a pair of mid-stage studies evaluating weight loss and safety sending its stock $GPCR up nearly 55% on Monday morning. https://endpts.com/structures-oral-glp-1-produces-comparable-weight-loss-to-lillys-oral-candidate/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/structures-oral-glp-1-produces-comparable-weight-loss-to-lillys-oral-candidate/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1797667148967592318) 2024-06-03T16:30Z 31.2K followers, [----] engagements "Maze Therapeutics files for 2025s first biotech IPO after a $115M Series D and neuroscience spinoff. Trading as $MAZE the IPO aims to reignite interest in biopharma public markets ahead of #JPM25. https://endpts.com/maze-files-for-first-biotech-ipo-of-2025-following-115m-funding-boost/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/maze-files-for-first-biotech-ipo-of-2025-following-115m-funding-boost/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1877041909429838195) 2025-01-08T17:17Z 31.2K followers, [----] engagements "Aardvark Therapeutics $94m IPO in February was the last biotech to go public this year in Wall Street. @ky_lahucik looks into the slump in public offerings. https://endpts.com/its-been-three-months-without-a-biotech-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/its-been-three-months-without-a-biotech-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1923406069168009244) 2025-05-16T15:51Z 31.2K followers, [---] engagements "CRISPR Therapeutics' called its latest gene editing tool a significant advance" over prime editing. But Prime Medicine disagrees. https://endpoints.news/crispr-therapeutics-says-its-new-gene-editing-tool-is-a-significant-advance-over-prime-editing-prime-medicine-disagrees/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/crispr-therapeutics-says-its-new-gene-editing-tool-is-a-significant-advance-over-prime-editing-prime-medicine-disagrees/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1980662177855074736) 2025-10-21T15:47Z 31.2K followers, [----] engagements "San Francisco is where the biopharma year takes shape. At Endpoints at #JPM26 were convening leaders to unpack whats driving the industry right now and what comes next. Our lineup includes conversations with Mike Doustdar (Novo Nordisk) Heather Turner (LB Pharmaceuticals) and Nobel Laureate Fred Ramsdell (Sonoma Biotherapeutics). Join us in SF or tune in virtually for free. Choose your pass: https://events.endpoints.news/jpm26/homeref=x https://events.endpoints.news/jpm26/homeref=x" [X Link](https://x.com/endpts/status/2008560595163922846) 2026-01-06T15:25Z 31.2K followers, [----] engagements "Amicus reveals that it had another suitor before making a $4.8B deal to sell itself to BioMarin. https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2014439826934690262) 2026-01-22T20:47Z 31.2K followers, [----] engagements "TRexBio has raised another $50M to expand its investment in Treg candidates. https://endpoints.news/trexbio-gets-another-50m-to-bring-more-treg-candidates-into-the-clinic/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/trexbio-gets-another-50m-to-bring-more-treg-candidates-into-the-clinic/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2016230509756760454) 2026-01-27T19:23Z 31.2K followers, [----] engagements "The FDA has put two Regenxbio gene therapy trials on hold after a patient developed a brain tumor dealing a setback to the biotech as it awaits a key approval decision. https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2016608554535268693) 2026-01-28T20:25Z 31.2K followers, [----] engagements "Amgen is pulling out of its immunology drug collaboration with Kyowa Kirin. The news comes as a surprise after the companies reported encouraging results and prepared for submission later this year. https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2017301117890117866) 2026-01-30T18:17Z 31.2K followers, [----] engagements "AstraZeneca joins the race for obesity pills with an announcement of promising Phase [--] results for its oral GLP-1. https://endpoints.news/astrazenecas-obesity-pill-hits-in-phase-2-key-cancer-trials-pushed-back/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazenecas-obesity-pill-hits-in-phase-2-key-cancer-trials-pushed-back/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2021239542372520028) 2026-02-10T15:07Z 31.2K followers, [----] engagements "🚨 Moderna accuses FDA of shifting trial standard after agency refuses to review flu shot https://endpoints.news/moderna-accuses-fda-of-shifting-standard-as-agency-refuses-flu-shot-review/ https://endpoints.news/moderna-accuses-fda-of-shifting-standard-as-agency-refuses-flu-shot-review/" [X Link](https://x.com/endpts/status/2021365700997120053) 2026-02-10T23:28Z 31.2K followers, [----] engagements "Upstream Bio said its TSLP-targeting drug cut severe asthma flare-ups by 56% in a Phase [--] trial. https://endpoints.news/upstream-bio-says-verekitug-delivered-positive-data-in-phase-2-severe-asthma-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/upstream-bio-says-verekitug-delivered-positive-data-in-phase-2-severe-asthma-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2021638490321215550) 2026-02-11T17:32Z 31.2K followers, [----] engagements "Sanofi is replacing CEO Paul Hudson with Merck KGaAs Beln Garijo who will take the helm as the pharma faces pipeline setbacks and looming biosimilar pressure on Dupixent. https://endpoints.news/sanofis-paul-hudson-out-as-belen-garijo-steps-in-as-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-paul-hudson-out-as-belen-garijo-steps-in-as-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/anyuser/status/2021972373667557776) 2026-02-12T15:39Z 31.2K followers, [----] engagements "Controversy is mounting around FDA vaccines chief Vinay Prasad following the agencys rejection of Modernas flu shot and new reports of internal personnel complaints. https://endpoints.news/controversy-around-fdas-prasad-rises-again-after-moderna-rejection-behavior-allegations/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/controversy-around-fdas-prasad-rises-again-after-moderna-rejection-behavior-allegations/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2022037278047240658) 2026-02-12T19:57Z 31.2K followers, [----] engagements "Ultragenyx cuts [---] jobs 10% of its workforce following a tough [----]. https://endpoints.news/ultragenyx-to-lay-off-about-130-employees-after-rough-2025/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ultragenyx-to-lay-off-about-130-employees-after-rough-2025/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/anyuser/status/2022290019768033444) 2026-02-13T12:41Z 31.2K followers, [----] engagements "PTC Therapeutics has withdrawn its NDA resubmission for a Duchenne treatment after the FDA doubted the data would meet its effectiveness threshold. https://endpoints.news/ptc-therapeutics-withdraws-us-filing-for-troubled-duchenne-treatment-translarna/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ptc-therapeutics-withdraws-us-filing-for-troubled-duchenne-treatment-translarna/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/anyuser/status/2022317331091746897) 2026-02-13T14:29Z 31.2K followers, [----] engagements "💼In this week's Peer Review: Paul Hudson hands over the baton for Sanofi's leadership to Beln Garijo adding to the flurry of CEO changes in big pharma. https://endpoints.news/paul-hudson-couldnt-quite-get-sanofi-over-the-hump-protac-developer-arvinas-appoints-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/paul-hudson-couldnt-quite-get-sanofi-over-the-hump-protac-developer-arvinas-appoints-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/anyuser/status/2022339383781896360) 2026-02-13T15:57Z 31.2K followers, [---] engagements "CRISPR pioneer Feng Zhang's company is pivoting into siRNA obesity therapies. "If you can do it with siRNA its really hard to argue you should do it some other way" Moonwalk's CEO told @RLCscienceboss. https://endpoints.news/epigenetic-editing-startup-moonwalk-shifts-focus-to-sirna-for-obesity/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/epigenetic-editing-startup-moonwalk-shifts-focus-to-sirna-for-obesity/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/anyuser/status/2022377459484664289) 2026-02-13T18:28Z 31.2K followers, 30.1K engagements "Moderna is noncommittal on [----] break-even guidance after the FDA declined to review its flu shot. https://endpoints.news/modernas-flu-shot-dilemma-muddies-2028-break-even-guidance/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/modernas-flu-shot-dilemma-muddies-2028-break-even-guidance/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/anyuser/status/2022394355143909567) 2026-02-13T19:36Z 31.2K followers, [----] engagements "Checkmate Pharmaceuticals brings two new execs on board; Takeda sheds [--] drugs gains $200M in Acino deal https://endpts.com/checkmate-pharmaceuticals-brings-two-new-execs-on-board-relmada-presents-positive-results-for-depression-treatment/ https://endpts.com/checkmate-pharmaceuticals-brings-two-new-execs-on-board-relmada-presents-positive-results-for-depression-treatment/" [X Link](https://x.com/endpts/status/1184144573574123520) 2019-10-15T16:30Z 31.1K followers, [--] engagements "Checkmate Pharmaceuticals brings two new execs on board; Takeda sheds [--] drugs gains $200M in Acino deal $TAK https://endpts.com/checkmate-pharmaceuticals-brings-two-new-execs-on-board-relmada-presents-positive-results-for-depression-treatment/ https://endpts.com/checkmate-pharmaceuticals-brings-two-new-execs-on-board-relmada-presents-positive-results-for-depression-treatment/" [X Link](https://x.com/endpts/status/1184564421382807556) 2019-10-16T20:19Z 31.1K followers, [--] engagements "Eli Lilly vet jumps aboard Polaris Partners; Mirati shakes up its leadership team with new hires and promotions https://endpts.com/eli-lilly-vet-jumps-aboard-polaris-partners-mirati-shakes-up-its-leadership-team-with-new-hires-and-promotions/ https://endpts.com/eli-lilly-vet-jumps-aboard-polaris-partners-mirati-shakes-up-its-leadership-team-with-new-hires-and-promotions/" [X Link](https://x.com/endpts/status/1215665751484522497) 2020-01-10T16:04Z 31.1K followers, [--] engagements "Eli Lilly vet jumps aboard Polaris Partners; Mirati shakes up its leadership team with new hires and promotions $LLY $MRTX https://endpts.com/eli-lilly-vet-jumps-aboard-polaris-partners-mirati-shakes-up-its-leadership-team-with-new-hires-and-promotions/ https://endpts.com/eli-lilly-vet-jumps-aboard-polaris-partners-mirati-shakes-up-its-leadership-team-with-new-hires-and-promotions/" [X Link](https://x.com/endpts/status/1216368737055649794) 2020-01-12T14:38Z 31.1K followers, [--] engagements "About three years after splitting from Versant Ventures discovery group Pipeline Therapeutics has landed an $80 million Series C round to go much broader than the Roche-partnered program that birthed it. https://endpts.com/versant-spinout-lands-80m-to-go-much-broader-than-the-roche-partnership-that-birthed-it/ https://endpts.com/versant-spinout-lands-80m-to-go-much-broader-than-the-roche-partnership-that-birthed-it/" [X Link](https://x.com/endpts/status/1359863678691074049) 2021-02-11T13:55Z 31.1K followers, [--] engagements "Close to a year after pulling in its last private fundraise Chinese immuno-oncology biotech Adlai Nortye is back with another nine-figure round. https://endpts.com/a-chinese-i-o-biotech-looking-to-turn-around-an-old-novartis-program-gets-a-new-fundraise-after-launching-phiii-study/ https://endpts.com/a-chinese-i-o-biotech-looking-to-turn-around-an-old-novartis-program-gets-a-new-fundraise-after-launching-phiii-study/" [X Link](https://x.com/endpts/status/1415646562349457409) 2021-07-15T12:16Z 31.1K followers, [--] engagements "Artiva Biotherapeutics has elected not to move forward with an IPO. The San Diego cell therapy developer quietly disclosed its plans not to wade into the murky public waters in an SEC filing on Tuesday. https://endpts.com/an-nk-cell-therapy-biotech-pulls-ipo-ambitions-weeks-after-second-trial-clearance/ https://endpts.com/an-nk-cell-therapy-biotech-pulls-ipo-ambitions-weeks-after-second-trial-clearance/" [X Link](https://x.com/endpts/status/1587838192723451904) 2022-11-02T16:05Z 31.1K followers, [--] engagements "Artiva Biotherapeutics has elected not to move forward with an IPO. The San Diego cell therapy developer quietly disclosed its plans not to wade into the murky public waters in an SEC filing on Tuesday. https://endpts.com/an-nk-cell-therapy-biotech-pulls-ipo-ambitions-weeks-after-second-trial-clearance/ https://endpts.com/an-nk-cell-therapy-biotech-pulls-ipo-ambitions-weeks-after-second-trial-clearance/" [X Link](https://x.com/endpts/status/1588154034367582210) 2022-11-03T13:00Z 31.1K followers, [--] engagements "OS Therapies eyes accelerated approval for OST-HER2 after Phase 2b success in osteosarcoma. https://endpts.com/os-therapies-plots-expedited-approval-for-osteosarcoma-drug-after-phase-2-win/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/os-therapies-plots-expedited-approval-for-osteosarcoma-drug-after-phase-2-win/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term=" [X Link](https://x.com/endpts/status/1879568056340693020) 2025-01-15T16:35Z 31.1K followers, [----] engagements "Legend Biotech is ramping up Carvykti production as it eyes blockbuster status in [----] following $963M in sales last year. https://endpts.com/legend-to-double-carvykti-production-as-it-targets-blockbuster-status/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content= https://endpts.com/legend-to-double-carvykti-production-as-it-targets-blockbuster-status/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=" [X Link](https://x.com/endpts/status/1899854223216406847) 2025-03-12T16:05Z 31.1K followers, [---] engagements "Bausch + Lomb CEO Brent Saunders sat down with Endpoints @AndrewE_Dunn to discuss his turnaround plan AIs impact on jobs and why TrumpRx matters. https://endpoints.news/qa-bausch-lomb-ceo-brent-saunders-on-turnaround-ai-trumprx/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/qa-bausch-lomb-ceo-brent-saunders-on-turnaround-ai-trumprx/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1989083129529921969) 2025-11-13T21:29Z 31.1K followers, [----] engagements "Genmab scraps another ADC from Pro-foundBio deal. https://endpoints.news/genmab-cans-another-adc-from-profoundbio-deal-in-area-of-jjs-ambrx-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/genmab-cans-another-adc-from-profoundbio-deal-in-area-of-jjs-ambrx-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1990473106968678867) 2025-11-17T17:32Z 31.1K followers, [----] engagements "BioNTech and Bristol Myers reveal encouraging mid-stage breast cancer results for their PD-L1xVEGF-A bispecific antibody. https://endpoints.news/sabcs25-biontech-bms-unwrap-phase-2-data-for-pd-l1xvegf-bispecific-in-breast-cancer/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sabcs25-biontech-bms-unwrap-phase-2-data-for-pd-l1xvegf-bispecific-in-breast-cancer/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/1998420931052728692) 2025-12-09T15:54Z 31.1K followers, [----] engagements "AbbVie has struck a MFN deal to lower drug prices in Medicaid and will also participate in TrumpRx Trumps direct-to-patient platform expected to launch this year. https://endpoints.news/abbvie-reaches-mfn-deal-with-the-white-house-pledges-billions-to-us-manufacturing/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/abbvie-reaches-mfn-deal-with-the-white-house-pledges-billions-to-us-manufacturing/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2011143606434935022) 2026-01-13T18:29Z 31.1K followers, [----] engagements "Whos afraid of OpenAI Not digital health companies apparently. @ShelbyJLiv explores the potential competition posed by the AI giant in todays Health Tech. https://endpoints.news/whos-afraid-of-openai/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/whos-afraid-of-openai/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2011168133319692471) 2026-01-13T20:07Z 31.1K followers, [---] engagements "Think Bioscience raises $55M to unearth new drug pockets. https://endpoints.news/think-bioscience-gets-55m-to-unearth-new-drug-pockets/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/think-bioscience-gets-55m-to-unearth-new-drug-pockets/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2014024480746533254) 2026-01-21T17:17Z 31.1K followers, [----] engagements "J&J shrugs off MFN impact predicts strong growth for [----]. https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2014077352318271554) 2026-01-21T20:47Z 31.1K followers, [----] engagements "BioMarin vets lead new biotech with $82M for rare disease drugs. https://endpoints.news/biomarin-vets-spearhead-new-biotech-with-82m-for-rare-disease-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/biomarin-vets-spearhead-new-biotech-with-82m-for-rare-disease-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2014380694600905198) 2026-01-22T16:52Z 31.1K followers, [----] engagements "The FDA lifted a clinical hold on one of Intellias Phase [--] gene editing trials for transthyretin amyloidosis while a second pivotal study remains on pause. https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2016276891213107470) 2026-01-27T22:27Z 31.1K followers, [----] engagements "Exclusive: Formation Bio licensed a China-sourced drug hitting the same target as Abivaxs lead program aiming to follow its breakout success and move the asset into the clinic in [----]. https://endpoints.news/exclusive-following-abivax-formation-bio-licenses-mir-124-drug-from-china/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/exclusive-following-abivax-formation-bio-licenses-mir-124-drug-from-china/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2016947432156725729) 2026-01-29T18:51Z 31.1K followers, [----] engagements "The White House has postponed the planned launch event for TrumpRx the administrations direct-to-consumer drug pricing platform with no new date announced. https://endpoints.news/white-house-postpones-planned-trumprx-launch-event/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/white-house-postpones-planned-trumprx-launch-event/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2016972968920821965) 2026-01-29T20:33Z 31.1K followers, [----] engagements "Summit says the FDA will decide by Nov. [--] on ivonescimab its bispecific cancer drug marking a key test for a new class of immuno-oncology therapies. https://endpoints.news/summit-gets-november-pdufa-date-for-its-pd-1xvegf-bispecific/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/summit-gets-november-pdufa-date-for-its-pd-1xvegf-bispecific/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=" [X Link](https://x.com/endpts/status/2016983201114161616) 2026-01-29T21:14Z 31.1K followers, [----] engagements "Decades into the making Kyowa Hakko Kirin wins FDA approval for add-on #Parkinson's therapy $KYKOF https://endpts.com/decades-into-the-making-kyowa-hakko-kirin-wins-fda-approval-for-add-on-parkinsons-therapy/ https://endpts.com/decades-into-the-making-kyowa-hakko-kirin-wins-fda-approval-for-add-on-parkinsons-therapy/" [X Link](https://x.com/endpts/status/1166828806193197058) 2019-08-28T21:44Z 30.8K followers, [--] engagements "After disappointing investors SillaJen gets into trouble with Korean prosecutors on suspected insider trading https://endpts.com/after-disappointing-investors-sillajen-gets-into-trouble-with-korean-prosecutors-on-suspected-insider-trading/ https://endpts.com/after-disappointing-investors-sillajen-gets-into-trouble-with-korean-prosecutors-on-suspected-insider-trading/" [X Link](https://x.com/endpts/status/1167041345145442304) 2019-08-29T11:48Z 30.9K followers, [--] engagements "After disappointing investors #SillaJen gets into trouble with Korean prosecutors on suspected insider trading https://endpts.com/after-disappointing-investors-sillajen-gets-into-trouble-with-korean-prosecutors-on-suspected-insider-trading/ https://endpts.com/after-disappointing-investors-sillajen-gets-into-trouble-with-korean-prosecutors-on-suspected-insider-trading/" [X Link](https://x.com/endpts/status/1167268703802728448) 2019-08-30T02:52Z 30.9K followers, [--] engagements "SK Biopharmaceuticals emerges from pandemic delays with pitch for $822M IPO https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/ https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/" [X Link](https://x.com/endpts/status/1272547989207343104) 2020-06-15T15:14Z 30.8K followers, [--] engagements "SK Biopharmaceuticals emerges from pandemic delays with pitch for $822M #IPO https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/ https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/" [X Link](https://x.com/endpts/status/1272700924516012033) 2020-06-16T01:22Z 30.8K followers, [--] engagements "UK and Vertex finally reach CF deal; FDA OKs third Ultragenyx drug $VRTX $RARE https://endpts.com/uk-and-vertex-finally-reach-cf-deal-fda-oks-third-ultragenyx-drug/ https://endpts.com/uk-and-vertex-finally-reach-cf-deal-fda-oks-third-ultragenyx-drug/" [X Link](https://x.com/endpts/status/1278563310011588613) 2020-07-02T05:37Z 30.8K followers, [--] engagements "FDA approvals roundup: Zogenix's Fintepla Ultragenyx's Dojolvi and Genentech's Phesgo https://endpts.com/fda-approvals-roundup-zogenixs-fintepla-ultragenyxs-dojolvi-and-genentechs-phesgo/ https://endpts.com/fda-approvals-roundup-zogenixs-fintepla-ultragenyxs-dojolvi-and-genentechs-phesgo/" [X Link](https://x.com/endpts/status/1278643968448888833) 2020-07-02T10:57Z 31.1K followers, [--] engagements "#FDA approvals roundup: Zogenix's Fintepla Ultragenyx's Dojolvi and Genentech's Phesgo https://endpts.com/fda-approvals-roundup-zogenixs-fintepla-ultragenyxs-dojolvi-and-genentechs-phesgo/ https://endpts.com/fda-approvals-roundup-zogenixs-fintepla-ultragenyxs-dojolvi-and-genentechs-phesgo/" [X Link](https://x.com/endpts/status/1278806657963827202) 2020-07-02T21:44Z 31.1K followers, [--] engagements "Roche declares a PhIII failure for Covid-19 as the IL-6 repurposing theory bites the dust $RHBBY https://endpts.com/roche-declares-a-phiii-failure-for-covid-19-as-the-il-6-repurposing-theory-bites-the-dust/ https://endpts.com/roche-declares-a-phiii-failure-for-covid-19-as-the-il-6-repurposing-theory-bites-the-dust/" [X Link](https://x.com/endpts/status/1288569739095269377) 2020-07-29T20:19Z 30.8K followers, [--] engagements "Kite founder Arie Belldegrun envisioned a club-like biotech compound at the site he was building with his son and Tishman Speyer in Seaport. Then CRISPR Therapeutics leased all [------] square feet of it. https://endpts.com/that-new-biotech-building-arie-belldegrun-co-has-been-building-in-seaport-it-turns-out-one-fast-growing-developer-took-the-whole-thing/ https://endpts.com/that-new-biotech-building-arie-belldegrun-co-has-been-building-in-seaport-it-turns-out-one-fast-growing-developer-took-the-whole-thing/" [X Link](https://x.com/endpts/status/1296930078019014663) 2020-08-21T22:00Z 31K followers, [--] engagements "Genmab axes an ADC development program after the data fail to impress https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/ https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/" [X Link](https://x.com/endpts/status/1331306667015802880) 2020-11-24T18:40Z 30.9K followers, [--] engagements "Genmab has decided to kill their program for enapotamab vedotin after the data gathered from expansion cohorts failed to measure up. https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/ https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/" [X Link](https://x.com/endpts/status/1331349372085288960) 2020-11-24T21:30Z 30.9K followers, [--] engagements "In today's News Briefing: CG Oncology has some new cash to play with. https://endpts.com/news-briefing-cg-oncology-nets-47m-series-d-for-bladder-cancer-studies-resolve-biosciences-raises-24m-in-series-a/ https://endpts.com/news-briefing-cg-oncology-nets-47m-series-d-for-bladder-cancer-studies-resolve-biosciences-raises-24m-in-series-a/" [X Link](https://x.com/endpts/status/1337570363920633857) 2020-12-12T01:30Z 31K followers, [--] engagements "Biotech Voices: "CRISPR has the potential to be one of the most revolutionary (or dangerous) genetic manipulation technologies ever developed" McDonnell Boehnen Hulbert & Berghoff's Kevin Noonan writes. https://endpts.com/the-continuing-crispr-patent-saga/ https://endpts.com/the-continuing-crispr-patent-saga/" [X Link](https://x.com/endpts/status/1379820962657542146) 2021-04-07T15:38Z 31K followers, [--] engagements "In today's News Briefing: BioTheryX is continuing to rake in investor capital netting a fresh $92 million Series E round on Thursday. https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/ https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/" [X Link](https://x.com/endpts/status/1395398616492167171) 2021-05-20T15:18Z 30.9K followers, [--] engagements "After revealing a flop on its second shot for alpha-1 antitrypsin deficiency Vertex plowed ahead with another data drop from its CRISPR Therapeutics partnership. And though the topline data proved positive concerns over conditioning agents linger. https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/ https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/" [X Link](https://x.com/endpts/status/1403319479027838978) 2021-06-11T11:53Z 30.9K followers, [--] engagements "After revealing a flop on its second shot for alpha-1 antitrypsin deficiency Vertex plowed ahead with another data drop from its CRISPR Therapeutics partnership. And though the topline data proved positive concerns over conditioning agents linger. https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/ https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/" [X Link](https://x.com/endpts/status/1403443166565437441) 2021-06-11T20:05Z 30.9K followers, [--] engagements "After revealing a flop on its second shot for alpha-1 antitrypsin deficiency Vertex plowed ahead with another data drop from its CRISPR Therapeutics partnership. And though the topline data proved positive concerns over conditioning agents linger. https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/ https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/" [X Link](https://x.com/endpts/status/1404166685117059077) 2021-06-13T20:00Z 30.9K followers, [--] engagements "CRISPR Therapeutics signed a deal with Capsida Biotherapeutics a gene therapy player specializing in AAV engineering to carve out a delivery mechanism for the companys gene editing tech in ALS and the rare neurodegenerative disorder Friedreichs ataxia. https://endpts.com/crispr-therapeutics-takes-a-swing-at-als-gene-editing-in-discovery-deal-with-aav-upstart-capsida/ https://endpts.com/crispr-therapeutics-takes-a-swing-at-als-gene-editing-in-discovery-deal-with-aav-upstart-capsida/" [X Link](https://x.com/endpts/status/1404766543624409090) 2021-06-15T11:43Z 30.9K followers, [--] engagements "WuXi Biologics Massachusetts manufacturing site isnt even up and running yet and its already getting an upgrade. https://endpts.com/wuxi-biologics-earns-local-nod-for-expansion-to-growing-ma-manufacturing-site/ https://endpts.com/wuxi-biologics-earns-local-nod-for-expansion-to-growing-ma-manufacturing-site/" [X Link](https://x.com/endpts/status/1430958220382777344) 2021-08-26T18:20Z 30.9K followers, [--] engagements "Bankruptcy judge: $JNJ can spin talc powder into different company potentially slowing plaintiffs' payouts https://endpts.com/bankruptcy-judge-jj-can-spin-talc-powder-into-different-company-potentially-slowing-plaintiffs-payouts/ https://endpts.com/bankruptcy-judge-jj-can-spin-talc-powder-into-different-company-potentially-slowing-plaintiffs-payouts/" [X Link](https://x.com/endpts/status/1431768564864888834) 2021-08-29T00:00Z 31K followers, [--] engagements "In today's News Briefing: Bluebird bio announced it completed the rolling submission of its BLA to the FDA for betibeglogene autotemcel gene therapy. https://endpts.com/bluebird-sends-blood-disorder-drug-to-fda-for-approval-cg-oncology-enters-collaboration-with-roche-for-tecentriq/ https://endpts.com/bluebird-sends-blood-disorder-drug-to-fda-for-approval-cg-oncology-enters-collaboration-with-roche-for-tecentriq/" [X Link](https://x.com/endpts/status/1440688411023593474) 2021-09-22T14:44Z 30.9K followers, [--] engagements "In today's #Covid19 roundup: AstraZeneca on Tuesday sought an EUA from the FDA for its long-acting antibody (LAAB) combination treatment which like the Regeneron mAb can be used prophylactically for symptomatic Covid-19. https://endpts.com/covid-19-roundup-astrazeneca-seeks-eua-for-long-acting-antibody-pfizer-vaccine-data-show-strength-against-delta-at-6-months/ https://endpts.com/covid-19-roundup-astrazeneca-seeks-eua-for-long-acting-antibody-pfizer-vaccine-data-show-strength-against-delta-at-6-months/" [X Link](https://x.com/endpts/status/1445353922785337351) 2021-10-05T11:43Z 30.9K followers, [--] engagements "Driven by innovation from biotech companies including Moderna BioNTech and Regeneron in Covid-19 vaccines and treatments the pharma industry is enjoying unprecedented positive public opinion. https://endpts.com/thanks-for-the-boost-biotech-pharma-industry-reputation-now-close-to-biotech-industry-esteem-harris-poll/ https://endpts.com/thanks-for-the-boost-biotech-pharma-industry-reputation-now-close-to-biotech-industry-esteem-harris-poll/" [X Link](https://x.com/endpts/status/1457347109305430022) 2021-11-07T14:00Z 30.9K followers, [--] engagements "Three years after Royalty Pharma chief Pablo Legorreta led a group of investors to buy up a pair of biotechs and create a startup called ProKidney the biotech is jumping straight into an $825 million public shell created by SPAC king Chamath Palihapitiya. https://endpts.com/billionaires-chamath-palihapitiya-and-pablo-legorreta-hatch-an-825m-spac-for-cell-therapy-biotech/ https://endpts.com/billionaires-chamath-palihapitiya-and-pablo-legorreta-hatch-an-825m-spac-for-cell-therapy-biotech/" [X Link](https://x.com/endpts/status/1483471948378222596) 2022-01-18T16:10Z 30.9K followers, [--] engagements "As Novartis CEO Vas Narasimhan figures out exactly what he wants to do with Sandoz the company revealed in its Q4 report that US sales for the generics unit are expected to continue on a downhill slide in the new year. https://endpts.com/vas-narasimhan-reveals-a-disappointing-outlook-for-novartis-generics-unit-while-laying-out-the-pharmas-ma-strategy/ https://endpts.com/vas-narasimhan-reveals-a-disappointing-outlook-for-novartis-generics-unit-while-laying-out-the-pharmas-ma-strategy/" [X Link](https://x.com/endpts/status/1488980552770211840) 2022-02-02T21:00Z 31K followers, [--] engagements "As Covid-19 has made it more difficult for US regulators to carry out routine inspections WuXi Biologics has been hit with unverified status causing its stock to sink and wipe $9.9 billion off of its market value before trading of its shares was halted. https://endpts.com/wuxi-stock-plummets-wiping-nearly-10b-off-market-value-as-us-adds-it-to-unverified-list/ https://endpts.com/wuxi-stock-plummets-wiping-nearly-10b-off-market-value-as-us-adds-it-to-unverified-list/" [X Link](https://x.com/endpts/status/1491096572540690432) 2022-02-08T17:08Z 31K followers, [--] engagements "Whatever Voyager is coming up with on its new gene therapy platform Novartis wants a piece of it. https://endpts.com/novartis-takes-a-gamble-on-voyagers-new-aav-tech-inks-1-5b-gene-therapy-discovery-pact/ https://endpts.com/novartis-takes-a-gamble-on-voyagers-new-aav-tech-inks-1-5b-gene-therapy-discovery-pact/" [X Link](https://x.com/endpts/status/1501173389972713472) 2022-03-08T12:30Z 30.9K followers, [--] engagements "Jumping into the M&A game Regeneron has scooped up a beaten down Checkmate Pharmaceuticals for $250 million in cash bagging its lead drug for melanoma. https://endpts.com/regeneron-buys-art-kriegs-biotech-startup-for-a-discount-price-boosting-i-o-pipeline/ https://endpts.com/regeneron-buys-art-kriegs-biotech-startup-for-a-discount-price-boosting-i-o-pipeline/" [X Link](https://x.com/endpts/status/1516388643488903168) 2022-04-19T12:10Z 31.1K followers, [--] engagements "WuXi Biologics may be inching closer to working its way off the US unverified list an event that wiped out some $10 billion in market value earlier this year. https://endpts.com/wuxi-biologics-inspection-raises-prospects-for-getting-off-us-unverified-list-report/ https://endpts.com/wuxi-biologics-inspection-raises-prospects-for-getting-off-us-unverified-list-report/" [X Link](https://x.com/endpts/status/1544291578914770944) 2022-07-05T12:06Z 31K followers, [--] engagements "Biogen filed suit against Sandoz earlier this month accusing the company of attempting to reap the benefits of Biogens hard work and success by allegedly infringing on Tysabris patent rights. https://endpts.com/unsealed-documents-detail-biogens-fight-against-sandoz-tysabri-biosimilar/ https://endpts.com/unsealed-documents-detail-biogens-fight-against-sandoz-tysabri-biosimilar/" [X Link](https://x.com/endpts/status/1572337303522922496) 2022-09-20T21:30Z 30.9K followers, [--] engagements "Weeks after announcing the spinoff of generics arm Sandoz Vas Narasimhan paints a picture of the new slimmer Novartis with a US-first mindset he said at an investor event on Thursday. https://endpts.com/novartis-unveils-us-first-strategy-ahead-of-sandoz-spinoff/ https://endpts.com/novartis-unveils-us-first-strategy-ahead-of-sandoz-spinoff/" [X Link](https://x.com/endpts/status/1573030109598154759) 2022-09-22T19:22Z 30.9K followers, [--] engagements "Weeks after announcing the spinoff of generics arm Sandoz Vas Narasimhan paints a picture of the new slimmer Novartis with a US-first mindset he said at an investor event on Thursday. https://endpts.com/novartis-unveils-us-first-strategy-ahead-of-sandoz-spinoff/ https://endpts.com/novartis-unveils-us-first-strategy-ahead-of-sandoz-spinoff/" [X Link](https://x.com/endpts/status/1573794404887691264) 2022-09-24T22:00Z 30.8K followers, [--] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@endpts Endpoints News
Endpoints News posts on X about ipo, novartis, ceo, $abbv the most. They currently have [------] followers and [---] posts still getting attention that total [------] engagements in the last [--] hours.
Engagements: [------] #
- [--] Week [------] -29%
- [--] Month [-------] +120%
- [--] Months [-------] +101%
- [--] Year [-------] +203%
Mentions: [--] #
- [--] Month [--] -37%
- [--] Months [---] +51%
- [--] Year [---] +140%
Followers: [------] #
- [--] Week [------] +0.12%
- [--] Month [------] +0.49%
- [--] Months [------] +3%
- [--] Year [------] +6.20%
CreatorRank: [-------] #
Social Influence
Social category influence stocks finance vc firms countries technology brands travel destinations celebrities exchanges cryptocurrencies us election
Social topic influence ipo, novartis, ceo #767, $abbv, sanofi #46, eli lilly, china, acquisition, $pfe, ai
Top accounts mentioned or mentioned by @johncendpts @armstrongdrew @rlcscienceboss @kylahucik @andrewedunn @maxonwifi @shelbyjliv @maxgelman @adrianradocea @tsrandall @wearehims @bylizc @andybiotech @cnbc @astrazenecas @leileiwuu @sarepta @formationbio @xairathera @sanofi
Top assets mentioned Novartis AG (NVS) AbbVie Inc (ABBV) Sanofi (SNY) Eli Lilly and Company (LLY) Pfizer, Inc. (PFE) Johnson & Johnson (JNJ) Bristol-Myers Squibb Co (BMY) Passage Bio, Inc. (PASG) Biogen Inc (BIIB)
Top Social Posts
Top posts by engagements in the last [--] hours
"The Carlyle Group shelled out $435 million to acquire more than 90% of Unchained Labs a six-year-old California-based firm from Danish asset manager Novo Holdings and VC firms TPG Biotech and Canaan Partners. https://endpts.com/the-carlyle-group-shells-out-435m-for-controlling-stake-in-vaccine-gene-therapy-services-company/ https://endpts.com/the-carlyle-group-shells-out-435m-for-controlling-stake-in-vaccine-gene-therapy-services-company/"
X Link 2021-04-26T15:14Z 31.1K followers, [--] engagements
"The Carlyle Group shelled out $435 million to acquire more than 90% of Unchained Labs a six-year-old California-based firm from Danish asset manager Novo Holdings and VC firms TPG Biotech and Canaan Partners. https://endpts.com/the-carlyle-group-shells-out-435m-for-controlling-stake-in-vaccine-gene-therapy-services-company/ https://endpts.com/the-carlyle-group-shells-out-435m-for-controlling-stake-in-vaccine-gene-therapy-services-company/"
X Link 2021-04-27T01:00Z 31.1K followers, [--] engagements
"Partnering up with a group of former collaborators Jo Viney is now guiding the ship at Seismic Therapeutic a Polaris Partners-incubated immunology player that debuted Wednesday with a whopping $101 million A series. https://endpts.com/two-pandion-vets-jump-back-into-the-startup-world-this-time-using-machine-learning-to-build-better-immunology-drugs/ https://endpts.com/two-pandion-vets-jump-back-into-the-startup-world-this-time-using-machine-learning-to-build-better-immunology-drugs/"
X Link 2022-02-09T13:23Z 31.2K followers, [--] engagements
"Partnering up with a group of former collaborators Jo Viney is now guiding the ship at Seismic Therapeutic a Polaris Partners-incubated immunology player that debuted Wednesday with a whopping $101 million A series. https://endpts.com/two-pandion-vets-jump-back-into-the-startup-world-this-time-using-machine-learning-to-build-better-immunology-drugs/ https://endpts.com/two-pandion-vets-jump-back-into-the-startup-world-this-time-using-machine-learning-to-build-better-immunology-drugs/"
X Link 2022-02-10T01:00Z 31.2K followers, [--] engagements
"Takeda has ended its work with Turnstone Biologics on a solid tumor asset that was in a Phase I/IIa study upending a [----] deal that had $900 million in biobucks on the line. https://endpts.com/takeda-axes-clinical-stage-program-in-turnstone-biologics-collaboration/ https://endpts.com/takeda-axes-clinical-stage-program-in-turnstone-biologics-collaboration/"
X Link 2022-07-28T16:18Z 31.2K followers, [--] engagements
"Novo Nordisk snaps up Forma Therapeutics in bid to beef up its sickle cell disease pipeline. https://endpts.com/as-novo-begins-phii-sickle-cell-trial-it-snags-a-later-stage-blood-disorder-drug-in-1-1b-forma-buy/ https://endpts.com/as-novo-begins-phii-sickle-cell-trial-it-snags-a-later-stage-blood-disorder-drug-in-1-1b-forma-buy/"
X Link 2022-09-01T15:50Z 31.1K followers, [--] engagements
"After launching Vividion Versant Ventures is back with what it calls a next-gen approach with Belharra Therapeutics. A $50 million Series A will kick things off for the small molecule developer. https://endpts.com/vividion-2-0-ben-cravatt-and-scripps-team-form-a-new-chemoproteomics-biotech/ https://endpts.com/vividion-2-0-ben-cravatt-and-scripps-team-form-a-new-chemoproteomics-biotech/"
X Link 2023-01-04T17:20Z 31.2K followers, [----] engagements
"CinCor Pharmas hypertension drug may have failed a Phase II study but that isn't stopping AstraZeneca from betting up to $1.8 billion on CinCor and the drug it licensed from Roche in [----]. https://endpts.com/astrazeneca-bets-up-to-1-8b-on-cincor-and-its-ex-roche-drug-for-hypertension/ https://endpts.com/astrazeneca-bets-up-to-1-8b-on-cincor-and-its-ex-roche-drug-for-hypertension/"
X Link 2023-01-09T16:10Z 31.1K followers, [----] engagements
"Gene therapy startup Coda Biotherapeutics has shut down Endpoints has learned. Investors Versant Ventures and MPM Capital declined to share further details about the closure https://endpts.com/biotech-pain-continues-as-versant-mpm-gene-therapy-startup-calls-it-quits/ https://endpts.com/biotech-pain-continues-as-versant-mpm-gene-therapy-startup-calls-it-quits/"
X Link 2023-03-08T13:20Z 31.2K followers, [----] engagements
"Out of biotech investor Versant Ventures comes immunology player Santa Ana Bio which recently closed a Series A round and will emerge from stealth later this year https://endpts.com/versants-new-immunology-biotech-santa-ana-bio-snags-series-a-with-gv-tpg-partners-on-board/ https://endpts.com/versants-new-immunology-biotech-santa-ana-bio-snags-series-a-with-gv-tpg-partners-on-board/"
X Link 2023-03-10T17:28Z 31.2K followers, [----] engagements
"Codiak BioSciences has ended its 8-year journey filing for bankruptcy as it searches for a bidder "as soon as reasonably practicable" https://endpts.com/codiak-files-for-chapter-11-bankruptcy-as-most-executives-head-for-the-exit/ https://endpts.com/codiak-files-for-chapter-11-bankruptcy-as-most-executives-head-for-the-exit/"
X Link 2023-03-27T18:21Z 31.1K followers, [----] engagements
"Biogens $7.3 billion acquisition of Reata Pharmaceuticals its first major deal in more than four years came after a showdown with another potential buyer that saw the acquisition price pushed up from $140 a share to $172.50 $BIIB $RETA https://endpts.com/biogens-7-3b-deal-for-reata-came-after-outbidding-mysterious-party-a/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/biogens-7-3b-deal-for-reata-came-after-outbidding-mysterious-party-a/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2023-08-14T16:10Z 31.1K followers, [----] engagements
"Theseus Pharmaceuticals lays off most workers and seeks 'strategic alternatives' after cancer pipeline failure https://endpts.com/theseus-pharmaceuticals-lays-off-most-workers-and-seeks-strategic-alternatives-after-cancer-pipeline-failure/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/theseus-pharmaceuticals-lays-off-most-workers-and-seeks-strategic-alternatives-after-cancer-pipeline-failure/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2023-11-14T12:31Z 31.1K followers, [----] engagements
"Last years layoffs were just the start for Vir Biotechnology. https://endpts.com/virs-overhaul-brings-an-end-to-most-virology-work-and-a-beginning-with-cancer/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/virs-overhaul-brings-an-end-to-most-virology-work-and-a-beginning-with-cancer/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-08-01T20:31Z 31.2K followers, [----] engagements
"Poseida Therapeutics said that [--] of [--] patients (91%) responded to the allogeneic CAR-T therapy its developing with Roche when given a higher dose of a chemo drug called cyclophosphamide than is typical. https://endpts.com/poseida-shares-incremental-phase-1-update-for-roche-partnered-off-the-shelf-car-t/utm_medium=organic_social&utm_campaign=&utm_source=twitter&utm_content=&utm_term= https://endpts.com/poseida-shares-incremental-phase-1-update-for-roche-partnered-off-the-shelf-car-t/utm_medium=organic_social&utm_campaign=&utm_source=twitter&utm_content=&utm_term="
X Link 2024-10-01T09:41Z 31.1K followers, [----] engagements
"Alto Neurosciences stock tumbled 60% on Wednesday morning the day after the company said a mid-stage trial for its oral small molecule failed to improve symptoms of major depressive disorder. https://endpts.com/alto-neurosciences-mid-stage-trial-misses-primary-endpoint-in-depression/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/alto-neurosciences-mid-stage-trial-misses-primary-endpoint-in-depression/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-10-23T16:14Z 31.2K followers, [----] engagements
"A fusion of this years buzziest biotech trends artificial intelligence and obesity drugs is the focus of a new startup backed with $53.5 million from biotech investors Versant Ventures and DCVC. https://endpts.com/exclusive-university-of-toronto-spinout-raises-53-5m-to-create-new-obesity-drugs-with-ai/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/exclusive-university-of-toronto-spinout-raises-53-5m-to-create-new-obesity-drugs-with-ai/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-10-24T15:08Z 31.1K followers, [---] engagements
"Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday. https://endpts.com/tyra-biosciences-gives-a-first-look-at-its-challenge-to-jjs-targeted-bladder-cancer-drug-balversa/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/tyra-biosciences-gives-a-first-look-at-its-challenge-to-jjs-targeted-bladder-cancer-drug-balversa/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-10-25T15:45Z 31.1K followers, [---] engagements
"ALK-Abell Pharmaceuticals pays $145M upfront and will get exclusive rights to ARS Pharmaceuticals anaphylaxis drug neffy in all markets except the US Australia New Zealand Japan and China according to a Saturday release. https://endpts.com/alk-abello-licenses-ars-anaphylaxis-nasal-spray-in-certain-markets-for-145m/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/alk-abello-licenses-ars-anaphylaxis-nasal-spray-in-certain-markets-for-145m/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-11-11T14:43Z 31.2K followers, [---] engagements
"Keros Therapeutics said Thursday morning it has voluntarily halted two of three dosing arms of its experimental drug in a Phase [--] trial due to a safety concern. https://endpts.com/keros-halts-parts-of-phase-2-pah-trial-due-to-safety-stock-tanks-70/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/keros-halts-parts-of-phase-2-pah-trial-due-to-safety-stock-tanks-70/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-12-12T21:04Z 31.1K followers, [----] engagements
"Pliant Therapeutics pauses enrollment and dosing in a mid-stage study of its lung fibrosis candidate following safety board recommendation. $PLRX was down 58% premarket Monday. https://endpts.com/pliant-shares-plummet-as-phase-2b-lung-fibrosis-study-paused/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/pliant-shares-plummet-as-phase-2b-lung-fibrosis-study-paused/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2025-02-10T14:39Z 31.1K followers, [----] engagements
"BeiGene halts Phase [--] trial of TIGIT drug ociperlimab in lung cancer after futility analysis adding to the string of TIGIT setbacks. https://endpts.com/another-tigit-trial-fails-as-beigene-scraps-phase-3-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/another-tigit-trial-fails-as-beigene-scraps-phase-3-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-04-03T20:09Z 31.1K followers, [----] engagements
"Zealand Pharma named Lilly alum Utpal Singh as its new chief science officer as the company works to leverage a $5.3B obesity deal with Roche into becoming a "generational biotech. https://endpts.com/with-aims-to-become-a-generational-biotech-zealand-pharma-hires-lilly-veteran-as-science-chief/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/with-aims-to-become-a-generational-biotech-zealand-pharma-hires-lilly-veteran-as-science-chief/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-04-23T19:28Z 31.1K followers, [----] engagements
"ALX Oncologys evorpacept failed two Phase [--] trials in head and neck cancer when combined with Mercks Keytruda. https://endpts.com/alx-oncology-reports-phase-2-failures-for-cd47-drug-combo-with-keytruda/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/alx-oncology-reports-phase-2-failures-for-cd47-drug-combo-with-keytruda/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-04-25T19:20Z 31.1K followers, [----] engagements
"Vor Biopharma is ending its clinical programs and laying off 95% of staff as the company founded by Siddhartha Mukherjee seeks a buyer or strategic deal. https://endpts.com/blood-cancer-biotech-vor-bio-ends-clinical-work-lays-off-95-of-staff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/blood-cancer-biotech-vor-bio-ends-clinical-work-lays-off-95-of-staff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-05-08T17:23Z 31.2K followers, [----] engagements
"Lilly is acquiring Verve Therapeutics in a bid to expand its gene editing pipeline for up to $1.3B. https://endpoints.news/eli-lilly-to-buy-gene-editing-biotech-verve-therapeutics-for-up-to-1-3b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/eli-lilly-to-buy-gene-editing-biotech-verve-therapeutics-for-up-to-1-3b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-06-17T14:18Z 31.2K followers, [----] engagements
"LaNovaMerck's key oncology partnerjust got acquired by Hong-Kong firm Sino Biopharmaceutical for $951M. https://endpoints.news/mercks-partner-lanova-medicines-is-acquired-for-951m-by-sino-biopharmaceutical/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/mercks-partner-lanova-medicines-is-acquired-for-951m-by-sino-biopharmaceutical/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-07-15T20:02Z 31.1K followers, [----] engagements
"Exclusive: LB Pharmaceuticals is said to be working on IPOfor schizophrenia drug has hired advisors https://endpoints.news/lb-pharmaceuticals-is-said-to-be-working-on-ipo-for-schizophrenia-drugutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lb-pharmaceuticals-is-said-to-be-working-on-ipo-for-schizophrenia-drugutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-08-22T18:21Z 31.1K followers, [----] engagements
"Novartis plans to pay $12B in cash to buy Avidity Biosciences and its three neuromuscular drugs that could head to the FDA next year. https://endpoints.news/novartis-to-buy-rna-drugmaker-avidity-biosciences-for-12b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-to-buy-rna-drugmaker-avidity-biosciences-for-12b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-10-27T11:58Z 31.1K followers, [----] engagements
"Flagship and its startups unveiled new deals with GSK Merck KGaA and a major Saudi research institute as the investor and incubator expands its pharma alliances. https://endpoints.news/flagship-and-portfolio-companies-do-deals-with-gsk-merck-kgaa-and-saudi-arabia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/flagship-and-portfolio-companies-do-deals-with-gsk-merck-kgaa-and-saudi-arabia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-11-20T22:05Z 31.2K followers, [----] engagements
"Kymera's eczema pill shows Dupixent-like efficacy in an early-stage study in what could be a serious challenge to one of todays best-selling medicines. https://endpoints.news/kymeras-pill-looks-competitive-to-dupixent-in-phase-1b-eczema-study/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/kymeras-pill-looks-competitive-to-dupixent-in-phase-1b-eczema-study/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-12-08T14:35Z 31.1K followers, [----] engagements
"Dyne Therapeutics' Duchenne drug hit its primary endpoint in a pivotal study boosting dystrophin levels and positioning the exon 51skipping therapy for an FDA filing. https://endpoints.news/dyne-says-duchenne-drug-succeeds-in-pivotal-study-heads-to-fda-for-approval/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/dyne-says-duchenne-drug-succeeds-in-pivotal-study-heads-to-fda-for-approval/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-12-08T22:38Z 31.1K followers, [----] engagements
"Argenx stops late-stage trials of Vyvgart Hytrulo its thyroid eye disease candidate after an interim analysis found the studies were unlikely to succeed. https://endpoints.news/argenx-cans-thyroid-eye-disease-trials-of-vyvgart-hytrulo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/argenx-cans-thyroid-eye-disease-trials-of-vyvgart-hytrulo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-12-15T15:24Z 31.2K followers, [----] engagements
"Shionogi will acquire one of the only approved ALS drugs for $2.5B. https://endpoints.news/shionogi-will-pay-2-5b-to-acquire-one-of-the-only-approved-als-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/shionogi-will-pay-2-5b-to-acquire-one-of-the-only-approved-als-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-12-22T19:07Z 31.1K followers, [----] engagements
"Rare disease drugmaker argenx will have a new CEO soon. https://endpoints.news/argenx-to-elevate-massey-to-ceo-as-it-expands-rare-disease-business/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/argenx-to-elevate-massey-to-ceo-as-it-expands-rare-disease-business/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-05T21:40Z 31.2K followers, [----] engagements
"The first biotech acquisition of [----] is here: Amgen is buying Oxford spinout Dark Blue Therapeutics in a deal worth up to $840M adding a preclinical cancer drug to its pipeline. https://endpoints.news/amgen-to-acquire-dark-blue-therapeutics-for-up-to-840m/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/amgen-to-acquire-dark-blue-therapeutics-for-up-to-840m/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-06T18:50Z 31.2K followers, [----] engagements
"Novartis will pay $50M upfront to license a peptide-based radiopharma asset from Chinese-based Zonsen PepLib Biotech. https://endpoints.news/novartis-licenses-radiopharma-asset-from-chinese-biotech-for-50m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-licenses-radiopharma-asset-from-chinese-biotech-for-50m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-13T15:24Z 31.1K followers, [----] engagements
"#JPM26 Day [--] Yesterday we got an update from Amgen on its obesity shot MariTide and insights on the future of biopharma from Novo Nordisk's Mike Doustdar. We're reporting live: https://endpoints.news/jpm26-day-2-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-day-2-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-13T15:48Z 31.2K followers, [----] engagements
"Pfizer is selling its ViiV stake a specialist HIV company it created with GSK to Japan's Shionogi for $2.1B. https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-20T21:44Z 31.2K followers, [----] engagements
"💼In this week's Peer Review: Karin Bok becomes the latest ex-FDA deputy to move to Lilly; also FDA alum Amy Muhlberg takes over as AbbVie's director of US policy; and Angelini Pharma gets a new CEO. Read the full update: https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-23T16:34Z 31.2K followers, [----] engagements
"Sanofi's latest results for its next big immunology hope show mixed results once again. https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-23T21:05Z 31.1K followers, [----] engagements
"Novos Wegovy pill is off to an impressive start: Prescriptions are up 500% in the second week with more than [-----] last week according to BMO Capital Markets. https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-26T14:35Z 31.1K followers, [----] engagements
"Genmab won't enroll any new patients in its early-stage trial of ProfoundBio's cancer candidate. https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-26T21:07Z 31.2K followers, [----] engagements
"Drug pricing fights under the Inflation Reduction Act are piling up at the Supreme Court with Novartis becoming the sixth pharma company to file a challenge as the industrys legal battle reaches a critical stage. https://endpoints.news/ira-drug-pricing-petitions-pile-up-at-the-supreme-court/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ira-drug-pricing-petitions-pile-up-at-the-supreme-court/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-26T22:00Z 31.1K followers, [----] engagements
"Exclusive: Cellares raised $257M to expand its global cell therapy manufacturing footprint as it prepares for a potential IPO as early as the end of [----]. https://endpoints.news/cellares-raises-257m-to-fund-global-expansion-as-it-eyes-2027-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/cellares-raises-257m-to-fund-global-expansion-as-it-eyes-2027-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-28T19:20Z 31.1K followers, [----] engagements
"Sanofi says it has up to 15B to spend on deals this year with M&A and R&D key to easing the looming patent cliff for blockbuster Dupixent. https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-29T16:34Z 31.2K followers, [----] engagements
"AstraZeneca is committing $15B through [----] to expand R&D and manufacturing in China as the country cements its role as a global hub for drug development. https://endpoints.news/astrazeneca-makes-15b-bet-on-china-to-expand-manufacturing-and-rd/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-makes-15b-bet-on-china-to-expand-manufacturing-and-rd/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-29T22:33Z 31.1K followers, [----] engagements
"AstraZeneca is paying $1.2B upfront for CSPC's long-acting obesity drugs part of its commitment to invest $15B in China by [----]. https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-30T14:43Z 31.2K followers, [----] engagements
"One cancer drug steps back and obesity asset steps forward as Pfizer reports earnings. https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-03T15:02Z 31.1K followers, [----] engagements
"Two Stanford PhDs created an AI system for scientists last year; today they're launching their startup after raising $13.5M. World meet Phylo. https://endpoints.news/menlo-and-a16z-back-ai-scientist-startup-phylo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/menlo-and-a16z-back-ai-scientist-startup-phylo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-03T17:03Z 31.1K followers, [----] engagements
"AccurEdit raises $75M in a Series A to advance its CRISPR pipeline one of the largest rounds in the Chinese gene editing club. https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-03T20:20Z 31.1K followers, [----] engagements
"Novo Nordisk forecast a sales drop of at least 5% in [----] citing MFN pricing pressure sending its shares down more than 14% and dragging other obesity stocks with it. https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-03T21:30Z 31.1K followers, [----] engagements
"The rare pediatric PRV program is back. A government funding bill reauthorized the FDAs ability to issue pediatric priority review vouchers through [----] reviving a key incentive for rare disease drug development. https://endpoints.news/rare-pediatric-prv-program-reauthorized-until-2029-via-government-funding-law/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/rare-pediatric-prv-program-reauthorized-until-2029-via-government-funding-law/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-04T20:56Z 31.1K followers, [----] engagements
"Angitia raised a $130M Series D to advance three clinical-stage biologics for musculoskeletal diseases continuing momentum for the US-China biotech as it eyes a potential IPO. https://endpoints.news/angitia-gets-130m-series-d-for-pipeline-of-musculoskeletal-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/angitia-gets-130m-series-d-for-pipeline-of-musculoskeletal-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-05T18:22Z 31.1K followers, [---] engagements
"Flagship-backed Generate:Biomedicines has filed for an IPO just days after dosing its first Phase [--] patient setting up a major test for the AI biotech sector. https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-05T19:15Z 31.1K followers, [----] engagements
"Eikons IPO may be the biggest biotech debut in two years but the sharp valuation reset shows how tough the public markets remain for big-name big-money biotechs and what the next wave could face. https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-05T19:47Z 31.1K followers, [----] engagements
"Priovant Therapeutics heads to Phase [--] trial for its immune skin disease candidate after "landmark transformative" success in Phase [--]. https://endpoints.news/roivant-spinout-priovant-touts-phase-2-brepocitinib-data-in-cutaneous-sarcoidosis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/roivant-spinout-priovant-touts-phase-2-brepocitinib-data-in-cutaneous-sarcoidosis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-06T14:12Z 31.2K followers, [----] engagements
"🚨 US calls for investigation of @wearehims over GLP-1 drugs threatening 'decisive steps' Breaking news from @ShelbyJLiv https://endpoints.news/us-calls-for-doj-investigation-of-hims-over-glp-1-drugs/ https://endpoints.news/us-calls-for-doj-investigation-of-hims-over-glp-1-drugs/"
X Link 2026-02-06T23:13Z 31.2K followers, [----] engagements
"Adlai Nortye a Hangzhou China-based biotech with operations in North Brunswick NJ has applied to trade on the Hong Kong Exchange just days after scoring a fundraising round to pursue its license-heavy business model according to a Tuesday filing. https://endpts.com/a-novartis-castoff-with-a-troubled-past-headlines-chinese-biotechs-hong-kong-ipo-quest/ https://endpts.com/a-novartis-castoff-with-a-troubled-past-headlines-chinese-biotechs-hong-kong-ipo-quest/"
X Link 2021-07-21T12:38Z 31.2K followers, [--] engagements
"A month and a half after a short sell attack nearly brought Ginkgo Bioworks newly public shares to its knees the company took its largest step yet toward clearing its name. But it also revealed its currently the target of a Department of Justice probe. https://endpts.com/as-ginkgo-looks-to-clear-its-name-the-feds-have-come-sniffing-around-on-the-heels-of-short-sell-report/ https://endpts.com/as-ginkgo-looks-to-clear-its-name-the-feds-have-come-sniffing-around-on-the-heels-of-short-sell-report/"
X Link 2021-11-15T16:18Z 31.2K followers, [--] engagements
"When Sorrento first unveiled plans to take its subsidiary Scilex public by merging with the blank check company Vickers Vantage Corp I last December it was clinging to the tail-end of a fading SPAC boom in healthcare. But it's still marching ahead. https://endpts.com/going-against-the-current-sorrento-spins-out-pain-focused-subsidiary-in-140m-spac-deal/ https://endpts.com/going-against-the-current-sorrento-spins-out-pain-focused-subsidiary-in-140m-spac-deal/"
X Link 2022-03-18T15:09Z 31.2K followers, [--] engagements
"When Sorrento first unveiled plans to take its subsidiary Scilex public by merging with the blank check company Vickers Vantage Corp I last December it was clinging to the tail-end of a fading SPAC boom in healthcare. But it's still marching ahead. https://endpts.com/going-against-the-current-sorrento-spins-out-pain-focused-subsidiary-in-140m-spac-deal/ https://endpts.com/going-against-the-current-sorrento-spins-out-pain-focused-subsidiary-in-140m-spac-deal/"
X Link 2022-03-20T19:00Z 31.2K followers, [--] engagements
"Kelonia Therapeutics backed by VCs such as Horizons Ventures and Venrock officially launched Thursday after being in stealth for a little over a year and has a bit of a cash stash thanks to $50 million from a Series A. https://endpts.com/gene-therapy-outfit-emerges-from-stealth-with-big-ambitions-first-stop-car-t/ https://endpts.com/gene-therapy-outfit-emerges-from-stealth-with-big-ambitions-first-stop-car-t/"
X Link 2022-04-28T12:10Z 31.2K followers, [--] engagements
"The reasoning for withdrawing its IPO desires Artiva Biotherapeutics had a different big plan to share one that couldnt be done under the constraints of having an S-1 on file with the SEC. https://endpts.com/artiva-after-pulling-ipo-plans-partners-with-affimed-to-speed-up-nk-cell-therapy-combo/ https://endpts.com/artiva-after-pulling-ipo-plans-partners-with-affimed-to-speed-up-nk-cell-therapy-combo/"
X Link 2022-11-03T15:50Z 31.2K followers, [--] engagements
"Kronos Bio axes nearly one-fifth of staff to preserve cash for two cancer programs https://endpts.com/kronos-bio-axes-nearly-one-fifth-of-staff-to-preserve-cash-for-two-cancer-programs/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/kronos-bio-axes-nearly-one-fifth-of-staff-to-preserve-cash-for-two-cancer-programs/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2023-11-03T12:43Z 31.2K followers, [----] engagements
"Boundless Bio a cancer biotech with two different oral small molecules in Phase [--] testing eyes about $88.4 million in net proceeds from its proposed IPO. https://endpts.com/boundless-bio-seeks-88m-in-ipo-as-it-runs-two-ph1-cancer-trials/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/boundless-bio-seeks-88m-in-ipo-as-it-runs-two-ph1-cancer-trials/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-03-21T15:39Z 31.2K followers, [----] engagements
"LENZ Therapeutics plans to seek FDA approval for its investigational eye drops for presbyopia setting up the drug to compete against AbbVies Vuity and Orasis Pharmaceuticals Qlosi. https://endpts.com/lenz-therapeutics-plans-nda-submission-this-year-for-farsightedness-eye-drops/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/lenz-therapeutics-plans-nda-submission-this-year-for-farsightedness-eye-drops/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-04-03T16:15Z 31.2K followers, [----] engagements
"Regulatory RNA startup CAMP4 Therapeutics has inked another collaboration deal as it prepares for an initial public offering. https://endpts.com/camp4-preparing-for-ipo-announces-partnership-with-biomarin/utm_medium=organic_social&utm_campaign=&utm_source=twitter&utm_content=&utm_term= https://endpts.com/camp4-preparing-for-ipo-announces-partnership-with-biomarin/utm_medium=organic_social&utm_campaign=&utm_source=twitter&utm_content=&utm_term="
X Link 2024-10-01T15:57Z 31.2K followers, [---] engagements
"Adi Hoess describes himself as someone who likes to build companies focused on challenging technologies. Its fitting then that after spending more than a decade as CEO of German biotech Affimed hes moving to nanomedicine company ViaNautis Bio. https://endpts.com/exclusive-ex-affimed-ceo-heads-to-uk-nanomedicine-biotech-jami-rubin-leaves-boundless-bio-after-ipo/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-10-18T20:01Z 31.2K followers, [----] engagements
"Apogee Therapeutics is headed toward a Dupixent face-off next year as it looks to become the next generational biotech writes @ky_lahucik https://endpts.com/apogee-targets-dupixent-head-to-head-next-year-as-it-outlines-broad-pipeline-plans/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/apogee-targets-dupixent-head-to-head-next-year-as-it-outlines-broad-pipeline-plans/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-12-02T12:51Z 31.2K followers, [----] engagements
"Bristol Myers is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with Century Therapeutics for natural killer cell and T cell-based cancer treatments as part of its plans to save $1.5bn. https://endpts.com/bristol-myers-drops-cell-therapy-pacts-with-immatics-century-as-part-of-portfolio-review/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-12-16T17:09Z 31.2K followers, [----] engagements
"Sionna Therapeutics and Odyssey Therapeutics are the latest biotechs to try to go public filing for IPOs at the end of #JPM25 week. https://endpts.com/sionna-and-odyssey-end-jpm-week-with-ipo-filings/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/sionna-and-odyssey-end-jpm-week-with-ipo-filings/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2025-01-21T13:28Z 31.2K followers, [----] engagements
"ALX Oncology is eyeing a potential accelerated approval pathway for its CD47-targeting drug in gastric cancer after reporting more data from a Phase [--] trial. https://endpts.com/alx-oncology-to-make-case-for-accelerated-approval-with-evorpacept-in-gastric-cancer/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/alx-oncology-to-make-case-for-accelerated-approval-with-evorpacept-in-gastric-cancer/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2025-01-24T19:10Z 31.2K followers, [----] engagements
"Omega Therapeutics expects filing for bankruptcy within the next week just under a year after entering in an obesity partnership with Novo. https://endpts.com/omega-therapeutics-nears-bankruptcy-filing-lays-off-workers/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/omega-therapeutics-nears-bankruptcy-filing-lays-off-workers/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2025-02-04T16:06Z 31.2K followers, [----] engagements
"Concentra acquires Cargo Therapeutics marking its fifth deal this year. https://endpoints.news/shell-company-concentra-has-found-its-rhythm-with-cargo-therapeutics-as-its-latest-buyout-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/shell-company-concentra-has-found-its-rhythm-with-cargo-therapeutics-as-its-latest-buyout-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-07-08T18:47Z 31.2K followers, [----] engagements
"Century Therapeutics is cutting half of its workforce by the end of the third quarter. https://endpoints.news/century-therapeutics-lays-off-half-of-its-staff-cfo-departs-as-it-narrows-priorities/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/century-therapeutics-lays-off-half-of-its-staff-cfo-departs-as-it-narrows-priorities/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-07-11T20:41Z 31.2K followers, [----] engagements
"XOMA is acquiring HilleVax and Lava Therapeutics as the biotech royalty market heats up with deal sizes growing in [----] despite a slower pace. OrbiMed also raised $1.86B for a new royalty fund. https://endpoints.news/royalty-market-accelerates-as-xoma-acquires-two-biotechs-and-orbimed-bags-another-fund/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/royalty-market-accelerates-as-xoma-acquires-two-biotechs-and-orbimed-bags-another-fund/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-08-04T17:52Z 31.2K followers, [----] engagements
"IO Biotech is seeking FDA approval after its cancer vaccine narrowly failed a pivotal study for skin cancer. https://endpoints.news/io-biotech-to-seek-fda-filing-even-though-cancer-vaccine-narrowly-fails-pivotal-skin-cancer-study/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/io-biotech-to-seek-fda-filing-even-though-cancer-vaccine-narrowly-fails-pivotal-skin-cancer-study/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-08-11T19:31Z 31.2K followers, [----] engagements
"Novartis said it's buying Tourmaline Bio for $1.4B with the intent to gain a new heart drug. https://endpoints.news/novartis-to-spend-1-4b-on-tourmaline-bio-gaining-new-heart-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-to-spend-1-4b-on-tourmaline-bio-gaining-new-heart-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-09-09T15:18Z 31.2K followers, [---] engagements
"Tourmaline Bio's $1.4B buyout this month attracted a small bidding war new documents show with the final sale coming in $20 per share above the starting point. https://endpoints.news/tourmaline-attracted-small-bidding-war-before-1-4b-sale-to-novartis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/tourmaline-attracted-small-bidding-war-before-1-4b-sale-to-novartis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-09-29T19:12Z 31.2K followers, [----] engagements
"Tvardi's shares $TVRD crashed this morning after the company reported a mid-stage trial failure for its STAT3 candidate. https://endpoints.news/tvardis-stock-crashes-as-stat3-drug-fails-phase-2-after-dropouts-from-side-effects/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/tvardis-stock-crashes-as-stat3-drug-fails-phase-2-after-dropouts-from-side-effects/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-10-13T17:47Z 31.2K followers, [----] engagements
"Join us online today at [--] AM ET: Health tech data sharing and AI are redefining care under the Trump Administration. Hear from Hinge Healths Daniel Perez and experts at URA Oracle and the Digital Medicine Society. Don't miss it register now. https://events.endpoints.news/healthtech2025/9505283ref=twitter https://events.endpoints.news/healthtech2025/9505283ref=twitter"
X Link 2025-11-06T15:11Z 31.2K followers, [----] engagements
"Hinge Health CEO Daniel Perez spent two years prepping for an IPO then went live on the S&Ps worst day of the year. Heres how he pulled it off. https://endpoints.news/how-hinge-health-pulled-off-its-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/how-hinge-health-pulled-off-its-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-11-11T20:44Z 31.2K followers, [----] engagements
"After a year of major deals the PD-(L)1xVEGF bispecific race is heating up with Summit Pfizer-3SBio and BMS-BioNTech vying to shape cancers next frontier. https://endpoints.news/heres-how-the-pd-l1xvegf-bispecific-race-is-looking-so-far/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/heres-how-the-pd-l1xvegf-bispecific-race-is-looking-so-far/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-11-12T19:27Z 31.2K followers, [----] engagements
"Zealand Pharma paused development of its GLP-1/GLP-2 obesity drug dapiglutide to focus on higher-priority programs. https://endpoints.news/zealand-pauses-development-of-glp-1-glp-2-obesity-candidate/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/zealand-pauses-development-of-glp-1-glp-2-obesity-candidate/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-11-13T18:07Z 31.2K followers, [----] engagements
"Structure Therapeutics GLP-1 cut weight by a placebo-adjusted average of 11.3% in Phase [--] stacking up with oral contenders from Novo and Lilly and setting up Phase [--] plans. https://endpoints.news/structure-therapeutics-obesity-pill-stacks-up-with-novo-and-lilly-ascletis-also-reports-early-results/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/structure-therapeutics-obesity-pill-stacks-up-with-novo-and-lilly-ascletis-also-reports-early-results/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-12-08T21:09Z 31.2K followers, [----] engagements
"AbbVie struck another China deal paying $100M upfront for Zelgens DLL3-targeted T cell engager and adding up to $1.075B in potential milestones. https://endpoints.news/abbvie-does-t-cell-engager-deal-in-china-for-zelgens-dll3-targeted-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/abbvie-does-t-cell-engager-deal-in-china-for-zelgens-dll3-targeted-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-02T17:40Z 31.2K followers, [----] engagements
"#JPM26 day 3: As the conference winds down were tracking updates from WuXi AppTec and AbbVie plus reactions from Lillys CEO who says hes unfazed by rising competition. Follow along for the latest from San Francisco. https://endpoints.news/jpm26-day-3-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-day-3-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-14T16:13Z 31.2K followers, [----] engagements
"#JPM26 takeaway GLP-1s are hot. Every time you mention GLP-1 Im going to charge you $5. Im going to donate it to I dont know an injured Canadian seals fund or something like that" Sandoz CEO Richard Saynor said. https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-16T17:03Z 31.2K followers, [----] engagements
"Sanofi's rare disease drugs gets mixed results in late-stage trials with a win in Gaucher diseases and a loss in Fabry disease. https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-02T13:07Z 31.2K followers, [----] engagements
"Pfizer announced this morning that patients taking the Metsera-originated obesity injection lost 10.5% of their body weight in six months. But it wasn't enough to meet sky-high hopes. https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-03T15:01Z 31.2K followers, [----] engagements
"The FDA has handed a CRL to AstraZeneca for its self-injectable candidate for Lupus one month after it was approved in Europe. https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-03T16:13Z 31.2K followers, [----] engagements
"Eli Lilly beat sales expectations and is projecting major growth in [----] fueled by its tirzepatide franchise a sharp contrast to rival Novo Nordisks forecasted decline. https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-04T16:22Z 31.2K followers, [---] engagements
"Novartis expects generics to cut about $4B from [----] sales with Entresto taking a sharp hit in Q4 as competition ramps up. https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-04T17:05Z 31.2K followers, [----] engagements
"Veradermics pulled off a $256M upsized IPO for its oral version of Rogaine a debut that points to renewed investor appetite for biotech listings. https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-04T20:01Z 31.2K followers, 38.1K engagements
"🎙Post-Hoc Live today at 12pm ET: The big showdown between drugmakers and compounders is finally here.🥊 Join @ArmstrongDrew and @ShelbyJLiv as they dissect Hims' decision to sell low-cost GLP-1s. 🥊 https://endpoints.news/post-hoc-live-analyzing-the-novo-vs-hims-glp-1-showdown/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/post-hoc-live-analyzing-the-novo-vs-hims-glp-1-showdown/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-06T15:55Z 31.2K followers, [---] engagements
"🚨 Novo Nordisk is suing Hims for patent infringement of its semaglutide in both pill and injectable form. Last week Hims announced a compounded version of Wegovy pill (Novo's GLP-1) before reversing course on Saturday. https://endpoints.news/novo-nordisk-sues-hims-over-wegovy-patent-infringement-considers-seeking-hundreds-of-millions-in-damages/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-09T13:49Z 31.2K followers, [----] engagements
"Lilly is buying Orna for $2.4B the largest buyout of an in vivo cell therapy company to date. https://endpoints.news/lilly-joins-in-vivo-car-t-sprint-with-2-4b-orna-acquisition/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lilly-joins-in-vivo-car-t-sprint-with-2-4b-orna-acquisition/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-09T18:12Z 31.2K followers, [---] engagements
"Is AstraZeneca on track to meet its $80B revenue target https://endpoints.news/is-astrazeneca-on-track-to-meet-its-80b-revenue-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/is-astrazeneca-on-track-to-meet-its-80b-revenue-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-10T18:31Z 31.2K followers, [---] engagements
"Money keeps flowing for private obesity and MASH developers. Cascade is the latest biotech to receive a pool of capital about $72M. https://endpoints.news/shanghais-cascade-gets-72m-to-pursue-mash-obesity-and-diabetes-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/shanghais-cascade-gets-72m-to-pursue-mash-obesity-and-diabetes-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-10T20:29Z 31.2K followers, [----] engagements
"Clinical trials are getting more complex and more expensive with redundant standards and mounting data demands driving up costs just as China moves faster and cheaper. Endpoints @MaxGelman dives into the problem in todays Endpoints in Focus. https://endpoints.news/how-a-closet-full-of-ekg-machines-illustrates-pharmas-clinical-trial-cost-problem/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-11T20:21Z 31.2K followers, [----] engagements
"Serial entrepreneur Tillman Gerngross antibody play Adagio raced into a pivotal trial for its lead #Covid19 drug when it was less than a year old. Now crossover investors are rolling up the Brinks truck and that could spell an IPO in the offing. https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/ https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/"
X Link 2021-04-19T15:26Z 31.2K followers, [--] engagements
"Serial entrepreneur Tillman Gerngross antibody play Adagio raced into a pivotal trial for its lead #Covid19 drug when it was less than a year old. Now crossover investors are rolling up the Brinks truck and that could spell an IPO in the offing. https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/ https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/"
X Link 2021-04-19T20:30Z 31.2K followers, [--] engagements
"Tillman Gerngross certainly wasnt the first to tackle #Covid19 antibodies but he has reason to believe he and his team at Adagio could be the best. Now were getting a first peek at human preventative data for Adagios lead antibody. https://endpts.com/adagio-offers-first-peek-at-covid-19-antibody-data-with-preventative-numbers-that-may-rival-mrna-vaccines/ https://endpts.com/adagio-offers-first-peek-at-covid-19-antibody-data-with-preventative-numbers-that-may-rival-mrna-vaccines/"
X Link 2021-05-05T12:28Z 31.2K followers, [--] engagements
"Bioregnum: Tillman Gerngross is betting well over $500M that the pandemic will never really end. Heres the IPO pitch https://endpts.com/tillman-gerngross-is-betting-well-over-500m-that-the-pandemic-will-never-really-end-heres-the-ipo-pitch/ https://endpts.com/tillman-gerngross-is-betting-well-over-500m-that-the-pandemic-will-never-really-end-heres-the-ipo-pitch/"
X Link 2021-07-19T12:23Z 31.2K followers, [--] engagements
"Bioregnum: Tillman Gerngross is betting well over $500M that the pandemic will never really end. Heres the IPO pitch https://endpts.com/tillman-gerngross-is-betting-well-over-500m-that-the-pandemic-will-never-really-end-heres-the-ipo-pitch/ https://endpts.com/tillman-gerngross-is-betting-well-over-500m-that-the-pandemic-will-never-really-end-heres-the-ipo-pitch/"
X Link 2021-07-20T00:00Z 31.2K followers, [--] engagements
"In this week's Peer Review: Back in May Passage Bio CFO Richard Morris and CMO Gary Romano left within days of each other but this week the gene therapy player has found their replacements along with a chief commercial officer. https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/ https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/"
X Link 2021-07-23T14:50Z 31.2K followers, [--] engagements
"In this week's Peer Review: Back in May Passage Bio CFO Richard Morris and CMO Gary Romano left within days of each other but this week the gene therapy player has found their replacements along with a chief commercial officer. https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/ https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/"
X Link 2021-07-23T19:30Z 31.2K followers, [--] engagements
"In this week's Peer Review: Back in May Passage Bio CFO Richard Morris and CMO Gary Romano left within days of each other but this week the gene therapy player has found their replacements along with a chief commercial officer. https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/ https://endpts.com/jim-wilson-startup-passage-bio-plugs-in-cfo-cmo-tillman-gerngross-nabs-a-coo-familiar-with-covid-19-fight-at-pfizer-as-adagio-files-for-ipo/"
X Link 2021-07-25T16:00Z 31.2K followers, [--] engagements
"In today's #Covid19 roundup: Antibody legend Tillman Gerngross has inked a deal to develop Adagios lead candidate for the treatment and prevention of Covid-19 in southern Asia. https://endpts.com/covid-19-roundup-tillman-gerngross-inks-deal-to-bring-antibody-candidate-to-india-at-fdas-request-mrna-vaccine-makers-will-expand-trials-for-children-ages-5-11/ https://endpts.com/covid-19-roundup-tillman-gerngross-inks-deal-to-bring-antibody-candidate-to-india-at-fdas-request-mrna-vaccine-makers-will-expand-trials-for-children-ages-5-11/"
X Link 2021-07-27T14:33Z 31.2K followers, [--] engagements
"The biotech industry was set to end this week with another two major public debuts. The first company Tillman Gerngross antibody startup Adagio Therapeutics priced a $300 million-plus IPO. But the second WCG Clinical fell through on its IPO plans. https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/ https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/"
X Link 2021-08-06T15:20Z 31.2K followers, [--] engagements
"The biotech industry was set to end this week with another two major public debuts. The first company Tillman Gerngross antibody startup Adagio Therapeutics priced a $300 million-plus IPO. But the second WCG Clinical fell through on its IPO plans. https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/ https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/"
X Link 2021-08-07T20:00Z 31.2K followers, [--] engagements
"The biotech industry was set to end this week with another two major public debuts. The first company Tillman Gerngross antibody startup Adagio Therapeutics priced a $300 million-plus IPO. But the second WCG Clinical fell through on its IPO plans. https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/ https://endpts.com/tillman-gerngross-steers-a-biotech-unicorn-to-nasdaq-while-another-companys-ipo-plans-fizzle/"
X Link 2021-08-08T13:00Z 31.2K followers, [--] engagements
"Hot off of his biotech unicorn landing on the Nasdaq another project from the lab of Dartmouth College engineering professor Tillman Gerngross has made news as its been acquired by Repligen. https://endpts.com/tillman-gerngross-project-out-of-dartmouth-college-acquired-by-repligen/ https://endpts.com/tillman-gerngross-project-out-of-dartmouth-college-acquired-by-repligen/"
X Link 2021-09-24T12:36Z 31.2K followers, [--] engagements
"Avitide will now be owned by Repligen the company announced last Thursday in a move made to boost its proteins business. https://endpts.com/tillman-gerngross-project-out-of-dartmouth-college-acquired-by-repligen/ https://endpts.com/tillman-gerngross-project-out-of-dartmouth-college-acquired-by-repligen/"
X Link 2021-09-30T22:00Z 31.2K followers, [--] engagements
"Tillman Gerngross the rarely shy antibody expert has been warning for over a year that the virus behind #Covid19 would likely continue to mutate. As the world scrambles to face a new variant Omicron that prediction looks particularly prescient. https://endpts.com/tillman-gerngross-on-omicron-it-is-a-grim-situation-were-going-to-see-a-significant-drop-in-vaccine-efficacy/ https://endpts.com/tillman-gerngross-on-omicron-it-is-a-grim-situation-were-going-to-see-a-significant-drop-in-vaccine-efficacy/"
X Link 2021-11-29T12:41Z 31.2K followers, [--] engagements
"Tillman Gerngross the rarely shy antibody expert has been warning for over a year that the virus behind #Covid19 would likely continue to mutate. As the world scrambles to face a new variant Omicron that prediction looks particularly prescient. https://endpts.com/tillman-gerngross-on-omicron-it-is-a-grim-situation-were-going-to-see-a-significant-drop-in-vaccine-efficacy/ https://endpts.com/tillman-gerngross-on-omicron-it-is-a-grim-situation-were-going-to-see-a-significant-drop-in-vaccine-efficacy/"
X Link 2021-11-29T21:00Z 31.2K followers, [--] engagements
"When Harvard professor Leonard Zon told serial entrepreneur Tillman Gerngross he had a question Gerngross replied: The answer is antibodies. Whats the question Roughly three years later their company Amagma Therapeutics is emerging from stealth mode. https://endpts.com/antibody-legend-tillman-gerngross-introduces-his-latest-company-with-an-innovent-deal-already-lined-up/ https://endpts.com/antibody-legend-tillman-gerngross-introduces-his-latest-company-with-an-innovent-deal-already-lined-up/"
X Link 2022-01-18T16:05Z 31.2K followers, [--] engagements
"When Harvard professor Leonard Zon told serial entrepreneur Tillman Gerngross he had a question Gerngross replied: The answer is antibodies. Whats the question Roughly three years later their company Amagma Therapeutics is emerging from stealth mode. https://endpts.com/antibody-legend-tillman-gerngross-introduces-his-latest-company-with-an-innovent-deal-already-lined-up/ https://endpts.com/antibody-legend-tillman-gerngross-introduces-his-latest-company-with-an-innovent-deal-already-lined-up/"
X Link 2022-01-18T23:30Z 31.2K followers, [--] engagements
"On Wednesday evening Adagio put out a release saying that founding CEO Tillman Gerngross a high profile figure in the antibody world had resigned confirming an earlier SEC filing that he had agreed to leave. https://endpts.com/tillman-gerngross-makes-it-official-hes-out-as-ceo-as-troubled-adagio-vows-to-soldier-on/ https://endpts.com/tillman-gerngross-makes-it-official-hes-out-as-ceo-as-troubled-adagio-vows-to-soldier-on/"
X Link 2022-02-24T13:40Z 31.2K followers, [--] engagements
"Peer Review: As market volatility sweeps through the landscape CEO changes are ramping up and topping the list is Tillman Gerngross a force in the antibody space who hitched his wagon to finding another Covid-19 solution by co-founding Adagio. https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/ https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/"
X Link 2022-02-25T13:16Z 31.2K followers, [--] engagements
"Peer Review: As market volatility sweeps through the landscape CEO changes are ramping up and topping the list is Tillman Gerngross a force in the antibody space who hitched his wagon to finding another Covid-19 solution by co-founding Adagio. https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/ https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/"
X Link 2022-02-27T00:00Z 31.2K followers, [--] engagements
"Peer Review: As market volatility sweeps through the landscape CEO changes are ramping up and topping the list is Tillman Gerngross a force in the antibody space who hitched his wagon to finding another Covid-19 solution by co-founding Adagio. https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/ https://endpts.com/tillman-gerngross-leads-a-pack-of-ceos-out-the-door-with-eyes-on-pipeline-expansion-poseida-woos-a-gene-therapy-exec-from-novartis/"
X Link 2022-02-27T17:00Z 31.2K followers, [--] engagements
"A new competitor has emerged from stealth to challenge Vertex in cystic fibrosis. Sionna Therapeutics a Sanofi Genzyme spinout announced its launch with $111 million in Series B financing led by OrbiMed. https://endpts.com/orbimed-backed-biotech-looks-to-challenge-vertex-in-cystic-fibrosis-by-drugging-the-undruggable/ https://endpts.com/orbimed-backed-biotech-looks-to-challenge-vertex-in-cystic-fibrosis-by-drugging-the-undruggable/"
X Link 2022-04-19T20:00Z 31.2K followers, [--] engagements
"California biotech Applied Molecular Transport said today it will halt all R&D and seek 'strategic alternatives' https://endpts.com/applied-molecular-transport-prepares-to-close-up-shop-as-it-pauses-rd-replaces-ceo-lays-off-57/ https://endpts.com/applied-molecular-transport-prepares-to-close-up-shop-as-it-pauses-rd-replaces-ceo-lays-off-57/"
X Link 2023-03-28T13:13Z 31.2K followers, [----] engagements
"Generation Bio to lay off [--] employees in a difficult year for non-viral gene therapy biotechs https://endpts.com/generation-bio-to-lay-off-68-employees-in-a-difficult-year-for-non-viral-gene-therapy-biotechs/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/generation-bio-to-lay-off-68-employees-in-a-difficult-year-for-non-viral-gene-therapy-biotechs/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2023-11-29T17:43Z 31.2K followers, [----] engagements
"Structure Therapeutics oral GLP-1 hit all endpoints in a pair of mid-stage studies evaluating weight loss and safety sending its stock $GPCR up nearly 55% on Monday morning. https://endpts.com/structures-oral-glp-1-produces-comparable-weight-loss-to-lillys-oral-candidate/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/structures-oral-glp-1-produces-comparable-weight-loss-to-lillys-oral-candidate/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2024-06-03T16:30Z 31.2K followers, [----] engagements
"Maze Therapeutics files for 2025s first biotech IPO after a $115M Series D and neuroscience spinoff. Trading as $MAZE the IPO aims to reignite interest in biopharma public markets ahead of #JPM25. https://endpts.com/maze-files-for-first-biotech-ipo-of-2025-following-115m-funding-boost/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/maze-files-for-first-biotech-ipo-of-2025-following-115m-funding-boost/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2025-01-08T17:17Z 31.2K followers, [----] engagements
"Aardvark Therapeutics $94m IPO in February was the last biotech to go public this year in Wall Street. @ky_lahucik looks into the slump in public offerings. https://endpts.com/its-been-three-months-without-a-biotech-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpts.com/its-been-three-months-without-a-biotech-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-05-16T15:51Z 31.2K followers, [---] engagements
"CRISPR Therapeutics' called its latest gene editing tool a significant advance" over prime editing. But Prime Medicine disagrees. https://endpoints.news/crispr-therapeutics-says-its-new-gene-editing-tool-is-a-significant-advance-over-prime-editing-prime-medicine-disagrees/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/crispr-therapeutics-says-its-new-gene-editing-tool-is-a-significant-advance-over-prime-editing-prime-medicine-disagrees/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-10-21T15:47Z 31.2K followers, [----] engagements
"San Francisco is where the biopharma year takes shape. At Endpoints at #JPM26 were convening leaders to unpack whats driving the industry right now and what comes next. Our lineup includes conversations with Mike Doustdar (Novo Nordisk) Heather Turner (LB Pharmaceuticals) and Nobel Laureate Fred Ramsdell (Sonoma Biotherapeutics). Join us in SF or tune in virtually for free. Choose your pass: https://events.endpoints.news/jpm26/homeref=x https://events.endpoints.news/jpm26/homeref=x"
X Link 2026-01-06T15:25Z 31.2K followers, [----] engagements
"Amicus reveals that it had another suitor before making a $4.8B deal to sell itself to BioMarin. https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-22T20:47Z 31.2K followers, [----] engagements
"TRexBio has raised another $50M to expand its investment in Treg candidates. https://endpoints.news/trexbio-gets-another-50m-to-bring-more-treg-candidates-into-the-clinic/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/trexbio-gets-another-50m-to-bring-more-treg-candidates-into-the-clinic/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-27T19:23Z 31.2K followers, [----] engagements
"The FDA has put two Regenxbio gene therapy trials on hold after a patient developed a brain tumor dealing a setback to the biotech as it awaits a key approval decision. https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-28T20:25Z 31.2K followers, [----] engagements
"Amgen is pulling out of its immunology drug collaboration with Kyowa Kirin. The news comes as a surprise after the companies reported encouraging results and prepared for submission later this year. https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-30T18:17Z 31.2K followers, [----] engagements
"AstraZeneca joins the race for obesity pills with an announcement of promising Phase [--] results for its oral GLP-1. https://endpoints.news/astrazenecas-obesity-pill-hits-in-phase-2-key-cancer-trials-pushed-back/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazenecas-obesity-pill-hits-in-phase-2-key-cancer-trials-pushed-back/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-10T15:07Z 31.2K followers, [----] engagements
"🚨 Moderna accuses FDA of shifting trial standard after agency refuses to review flu shot https://endpoints.news/moderna-accuses-fda-of-shifting-standard-as-agency-refuses-flu-shot-review/ https://endpoints.news/moderna-accuses-fda-of-shifting-standard-as-agency-refuses-flu-shot-review/"
X Link 2026-02-10T23:28Z 31.2K followers, [----] engagements
"Upstream Bio said its TSLP-targeting drug cut severe asthma flare-ups by 56% in a Phase [--] trial. https://endpoints.news/upstream-bio-says-verekitug-delivered-positive-data-in-phase-2-severe-asthma-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/upstream-bio-says-verekitug-delivered-positive-data-in-phase-2-severe-asthma-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-11T17:32Z 31.2K followers, [----] engagements
"Sanofi is replacing CEO Paul Hudson with Merck KGaAs Beln Garijo who will take the helm as the pharma faces pipeline setbacks and looming biosimilar pressure on Dupixent. https://endpoints.news/sanofis-paul-hudson-out-as-belen-garijo-steps-in-as-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-paul-hudson-out-as-belen-garijo-steps-in-as-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-12T15:39Z 31.2K followers, [----] engagements
"Controversy is mounting around FDA vaccines chief Vinay Prasad following the agencys rejection of Modernas flu shot and new reports of internal personnel complaints. https://endpoints.news/controversy-around-fdas-prasad-rises-again-after-moderna-rejection-behavior-allegations/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/controversy-around-fdas-prasad-rises-again-after-moderna-rejection-behavior-allegations/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-12T19:57Z 31.2K followers, [----] engagements
"Ultragenyx cuts [---] jobs 10% of its workforce following a tough [----]. https://endpoints.news/ultragenyx-to-lay-off-about-130-employees-after-rough-2025/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ultragenyx-to-lay-off-about-130-employees-after-rough-2025/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-13T12:41Z 31.2K followers, [----] engagements
"PTC Therapeutics has withdrawn its NDA resubmission for a Duchenne treatment after the FDA doubted the data would meet its effectiveness threshold. https://endpoints.news/ptc-therapeutics-withdraws-us-filing-for-troubled-duchenne-treatment-translarna/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ptc-therapeutics-withdraws-us-filing-for-troubled-duchenne-treatment-translarna/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-13T14:29Z 31.2K followers, [----] engagements
"💼In this week's Peer Review: Paul Hudson hands over the baton for Sanofi's leadership to Beln Garijo adding to the flurry of CEO changes in big pharma. https://endpoints.news/paul-hudson-couldnt-quite-get-sanofi-over-the-hump-protac-developer-arvinas-appoints-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/paul-hudson-couldnt-quite-get-sanofi-over-the-hump-protac-developer-arvinas-appoints-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-13T15:57Z 31.2K followers, [---] engagements
"CRISPR pioneer Feng Zhang's company is pivoting into siRNA obesity therapies. "If you can do it with siRNA its really hard to argue you should do it some other way" Moonwalk's CEO told @RLCscienceboss. https://endpoints.news/epigenetic-editing-startup-moonwalk-shifts-focus-to-sirna-for-obesity/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/epigenetic-editing-startup-moonwalk-shifts-focus-to-sirna-for-obesity/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-13T18:28Z 31.2K followers, 30.1K engagements
"Moderna is noncommittal on [----] break-even guidance after the FDA declined to review its flu shot. https://endpoints.news/modernas-flu-shot-dilemma-muddies-2028-break-even-guidance/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/modernas-flu-shot-dilemma-muddies-2028-break-even-guidance/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-02-13T19:36Z 31.2K followers, [----] engagements
"Checkmate Pharmaceuticals brings two new execs on board; Takeda sheds [--] drugs gains $200M in Acino deal https://endpts.com/checkmate-pharmaceuticals-brings-two-new-execs-on-board-relmada-presents-positive-results-for-depression-treatment/ https://endpts.com/checkmate-pharmaceuticals-brings-two-new-execs-on-board-relmada-presents-positive-results-for-depression-treatment/"
X Link 2019-10-15T16:30Z 31.1K followers, [--] engagements
"Checkmate Pharmaceuticals brings two new execs on board; Takeda sheds [--] drugs gains $200M in Acino deal $TAK https://endpts.com/checkmate-pharmaceuticals-brings-two-new-execs-on-board-relmada-presents-positive-results-for-depression-treatment/ https://endpts.com/checkmate-pharmaceuticals-brings-two-new-execs-on-board-relmada-presents-positive-results-for-depression-treatment/"
X Link 2019-10-16T20:19Z 31.1K followers, [--] engagements
"Eli Lilly vet jumps aboard Polaris Partners; Mirati shakes up its leadership team with new hires and promotions https://endpts.com/eli-lilly-vet-jumps-aboard-polaris-partners-mirati-shakes-up-its-leadership-team-with-new-hires-and-promotions/ https://endpts.com/eli-lilly-vet-jumps-aboard-polaris-partners-mirati-shakes-up-its-leadership-team-with-new-hires-and-promotions/"
X Link 2020-01-10T16:04Z 31.1K followers, [--] engagements
"Eli Lilly vet jumps aboard Polaris Partners; Mirati shakes up its leadership team with new hires and promotions $LLY $MRTX https://endpts.com/eli-lilly-vet-jumps-aboard-polaris-partners-mirati-shakes-up-its-leadership-team-with-new-hires-and-promotions/ https://endpts.com/eli-lilly-vet-jumps-aboard-polaris-partners-mirati-shakes-up-its-leadership-team-with-new-hires-and-promotions/"
X Link 2020-01-12T14:38Z 31.1K followers, [--] engagements
"About three years after splitting from Versant Ventures discovery group Pipeline Therapeutics has landed an $80 million Series C round to go much broader than the Roche-partnered program that birthed it. https://endpts.com/versant-spinout-lands-80m-to-go-much-broader-than-the-roche-partnership-that-birthed-it/ https://endpts.com/versant-spinout-lands-80m-to-go-much-broader-than-the-roche-partnership-that-birthed-it/"
X Link 2021-02-11T13:55Z 31.1K followers, [--] engagements
"Close to a year after pulling in its last private fundraise Chinese immuno-oncology biotech Adlai Nortye is back with another nine-figure round. https://endpts.com/a-chinese-i-o-biotech-looking-to-turn-around-an-old-novartis-program-gets-a-new-fundraise-after-launching-phiii-study/ https://endpts.com/a-chinese-i-o-biotech-looking-to-turn-around-an-old-novartis-program-gets-a-new-fundraise-after-launching-phiii-study/"
X Link 2021-07-15T12:16Z 31.1K followers, [--] engagements
"Artiva Biotherapeutics has elected not to move forward with an IPO. The San Diego cell therapy developer quietly disclosed its plans not to wade into the murky public waters in an SEC filing on Tuesday. https://endpts.com/an-nk-cell-therapy-biotech-pulls-ipo-ambitions-weeks-after-second-trial-clearance/ https://endpts.com/an-nk-cell-therapy-biotech-pulls-ipo-ambitions-weeks-after-second-trial-clearance/"
X Link 2022-11-02T16:05Z 31.1K followers, [--] engagements
"Artiva Biotherapeutics has elected not to move forward with an IPO. The San Diego cell therapy developer quietly disclosed its plans not to wade into the murky public waters in an SEC filing on Tuesday. https://endpts.com/an-nk-cell-therapy-biotech-pulls-ipo-ambitions-weeks-after-second-trial-clearance/ https://endpts.com/an-nk-cell-therapy-biotech-pulls-ipo-ambitions-weeks-after-second-trial-clearance/"
X Link 2022-11-03T13:00Z 31.1K followers, [--] engagements
"OS Therapies eyes accelerated approval for OST-HER2 after Phase 2b success in osteosarcoma. https://endpts.com/os-therapies-plots-expedited-approval-for-osteosarcoma-drug-after-phase-2-win/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/os-therapies-plots-expedited-approval-for-osteosarcoma-drug-after-phase-2-win/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="
X Link 2025-01-15T16:35Z 31.1K followers, [----] engagements
"Legend Biotech is ramping up Carvykti production as it eyes blockbuster status in [----] following $963M in sales last year. https://endpts.com/legend-to-double-carvykti-production-as-it-targets-blockbuster-status/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content= https://endpts.com/legend-to-double-carvykti-production-as-it-targets-blockbuster-status/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content="
X Link 2025-03-12T16:05Z 31.1K followers, [---] engagements
"Bausch + Lomb CEO Brent Saunders sat down with Endpoints @AndrewE_Dunn to discuss his turnaround plan AIs impact on jobs and why TrumpRx matters. https://endpoints.news/qa-bausch-lomb-ceo-brent-saunders-on-turnaround-ai-trumprx/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/qa-bausch-lomb-ceo-brent-saunders-on-turnaround-ai-trumprx/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-11-13T21:29Z 31.1K followers, [----] engagements
"Genmab scraps another ADC from Pro-foundBio deal. https://endpoints.news/genmab-cans-another-adc-from-profoundbio-deal-in-area-of-jjs-ambrx-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/genmab-cans-another-adc-from-profoundbio-deal-in-area-of-jjs-ambrx-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-11-17T17:32Z 31.1K followers, [----] engagements
"BioNTech and Bristol Myers reveal encouraging mid-stage breast cancer results for their PD-L1xVEGF-A bispecific antibody. https://endpoints.news/sabcs25-biontech-bms-unwrap-phase-2-data-for-pd-l1xvegf-bispecific-in-breast-cancer/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sabcs25-biontech-bms-unwrap-phase-2-data-for-pd-l1xvegf-bispecific-in-breast-cancer/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2025-12-09T15:54Z 31.1K followers, [----] engagements
"AbbVie has struck a MFN deal to lower drug prices in Medicaid and will also participate in TrumpRx Trumps direct-to-patient platform expected to launch this year. https://endpoints.news/abbvie-reaches-mfn-deal-with-the-white-house-pledges-billions-to-us-manufacturing/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/abbvie-reaches-mfn-deal-with-the-white-house-pledges-billions-to-us-manufacturing/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-13T18:29Z 31.1K followers, [----] engagements
"Whos afraid of OpenAI Not digital health companies apparently. @ShelbyJLiv explores the potential competition posed by the AI giant in todays Health Tech. https://endpoints.news/whos-afraid-of-openai/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/whos-afraid-of-openai/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-13T20:07Z 31.1K followers, [---] engagements
"Think Bioscience raises $55M to unearth new drug pockets. https://endpoints.news/think-bioscience-gets-55m-to-unearth-new-drug-pockets/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/think-bioscience-gets-55m-to-unearth-new-drug-pockets/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-21T17:17Z 31.1K followers, [----] engagements
"J&J shrugs off MFN impact predicts strong growth for [----]. https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-21T20:47Z 31.1K followers, [----] engagements
"BioMarin vets lead new biotech with $82M for rare disease drugs. https://endpoints.news/biomarin-vets-spearhead-new-biotech-with-82m-for-rare-disease-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/biomarin-vets-spearhead-new-biotech-with-82m-for-rare-disease-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-22T16:52Z 31.1K followers, [----] engagements
"The FDA lifted a clinical hold on one of Intellias Phase [--] gene editing trials for transthyretin amyloidosis while a second pivotal study remains on pause. https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-27T22:27Z 31.1K followers, [----] engagements
"Exclusive: Formation Bio licensed a China-sourced drug hitting the same target as Abivaxs lead program aiming to follow its breakout success and move the asset into the clinic in [----]. https://endpoints.news/exclusive-following-abivax-formation-bio-licenses-mir-124-drug-from-china/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/exclusive-following-abivax-formation-bio-licenses-mir-124-drug-from-china/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-29T18:51Z 31.1K followers, [----] engagements
"The White House has postponed the planned launch event for TrumpRx the administrations direct-to-consumer drug pricing platform with no new date announced. https://endpoints.news/white-house-postpones-planned-trumprx-launch-event/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/white-house-postpones-planned-trumprx-launch-event/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-29T20:33Z 31.1K followers, [----] engagements
"Summit says the FDA will decide by Nov. [--] on ivonescimab its bispecific cancer drug marking a key test for a new class of immuno-oncology therapies. https://endpoints.news/summit-gets-november-pdufa-date-for-its-pd-1xvegf-bispecific/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/summit-gets-november-pdufa-date-for-its-pd-1xvegf-bispecific/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="
X Link 2026-01-29T21:14Z 31.1K followers, [----] engagements
"Decades into the making Kyowa Hakko Kirin wins FDA approval for add-on #Parkinson's therapy $KYKOF https://endpts.com/decades-into-the-making-kyowa-hakko-kirin-wins-fda-approval-for-add-on-parkinsons-therapy/ https://endpts.com/decades-into-the-making-kyowa-hakko-kirin-wins-fda-approval-for-add-on-parkinsons-therapy/"
X Link 2019-08-28T21:44Z 30.8K followers, [--] engagements
"After disappointing investors SillaJen gets into trouble with Korean prosecutors on suspected insider trading https://endpts.com/after-disappointing-investors-sillajen-gets-into-trouble-with-korean-prosecutors-on-suspected-insider-trading/ https://endpts.com/after-disappointing-investors-sillajen-gets-into-trouble-with-korean-prosecutors-on-suspected-insider-trading/"
X Link 2019-08-29T11:48Z 30.9K followers, [--] engagements
"After disappointing investors #SillaJen gets into trouble with Korean prosecutors on suspected insider trading https://endpts.com/after-disappointing-investors-sillajen-gets-into-trouble-with-korean-prosecutors-on-suspected-insider-trading/ https://endpts.com/after-disappointing-investors-sillajen-gets-into-trouble-with-korean-prosecutors-on-suspected-insider-trading/"
X Link 2019-08-30T02:52Z 30.9K followers, [--] engagements
"SK Biopharmaceuticals emerges from pandemic delays with pitch for $822M IPO https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/ https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/"
X Link 2020-06-15T15:14Z 30.8K followers, [--] engagements
"SK Biopharmaceuticals emerges from pandemic delays with pitch for $822M #IPO https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/ https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/"
X Link 2020-06-16T01:22Z 30.8K followers, [--] engagements
"UK and Vertex finally reach CF deal; FDA OKs third Ultragenyx drug $VRTX $RARE https://endpts.com/uk-and-vertex-finally-reach-cf-deal-fda-oks-third-ultragenyx-drug/ https://endpts.com/uk-and-vertex-finally-reach-cf-deal-fda-oks-third-ultragenyx-drug/"
X Link 2020-07-02T05:37Z 30.8K followers, [--] engagements
"FDA approvals roundup: Zogenix's Fintepla Ultragenyx's Dojolvi and Genentech's Phesgo https://endpts.com/fda-approvals-roundup-zogenixs-fintepla-ultragenyxs-dojolvi-and-genentechs-phesgo/ https://endpts.com/fda-approvals-roundup-zogenixs-fintepla-ultragenyxs-dojolvi-and-genentechs-phesgo/"
X Link 2020-07-02T10:57Z 31.1K followers, [--] engagements
"#FDA approvals roundup: Zogenix's Fintepla Ultragenyx's Dojolvi and Genentech's Phesgo https://endpts.com/fda-approvals-roundup-zogenixs-fintepla-ultragenyxs-dojolvi-and-genentechs-phesgo/ https://endpts.com/fda-approvals-roundup-zogenixs-fintepla-ultragenyxs-dojolvi-and-genentechs-phesgo/"
X Link 2020-07-02T21:44Z 31.1K followers, [--] engagements
"Roche declares a PhIII failure for Covid-19 as the IL-6 repurposing theory bites the dust $RHBBY https://endpts.com/roche-declares-a-phiii-failure-for-covid-19-as-the-il-6-repurposing-theory-bites-the-dust/ https://endpts.com/roche-declares-a-phiii-failure-for-covid-19-as-the-il-6-repurposing-theory-bites-the-dust/"
X Link 2020-07-29T20:19Z 30.8K followers, [--] engagements
"Kite founder Arie Belldegrun envisioned a club-like biotech compound at the site he was building with his son and Tishman Speyer in Seaport. Then CRISPR Therapeutics leased all [------] square feet of it. https://endpts.com/that-new-biotech-building-arie-belldegrun-co-has-been-building-in-seaport-it-turns-out-one-fast-growing-developer-took-the-whole-thing/ https://endpts.com/that-new-biotech-building-arie-belldegrun-co-has-been-building-in-seaport-it-turns-out-one-fast-growing-developer-took-the-whole-thing/"
X Link 2020-08-21T22:00Z 31K followers, [--] engagements
"Genmab axes an ADC development program after the data fail to impress https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/ https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/"
X Link 2020-11-24T18:40Z 30.9K followers, [--] engagements
"Genmab has decided to kill their program for enapotamab vedotin after the data gathered from expansion cohorts failed to measure up. https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/ https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/"
X Link 2020-11-24T21:30Z 30.9K followers, [--] engagements
"In today's News Briefing: CG Oncology has some new cash to play with. https://endpts.com/news-briefing-cg-oncology-nets-47m-series-d-for-bladder-cancer-studies-resolve-biosciences-raises-24m-in-series-a/ https://endpts.com/news-briefing-cg-oncology-nets-47m-series-d-for-bladder-cancer-studies-resolve-biosciences-raises-24m-in-series-a/"
X Link 2020-12-12T01:30Z 31K followers, [--] engagements
"Biotech Voices: "CRISPR has the potential to be one of the most revolutionary (or dangerous) genetic manipulation technologies ever developed" McDonnell Boehnen Hulbert & Berghoff's Kevin Noonan writes. https://endpts.com/the-continuing-crispr-patent-saga/ https://endpts.com/the-continuing-crispr-patent-saga/"
X Link 2021-04-07T15:38Z 31K followers, [--] engagements
"In today's News Briefing: BioTheryX is continuing to rake in investor capital netting a fresh $92 million Series E round on Thursday. https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/ https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/"
X Link 2021-05-20T15:18Z 30.9K followers, [--] engagements
"After revealing a flop on its second shot for alpha-1 antitrypsin deficiency Vertex plowed ahead with another data drop from its CRISPR Therapeutics partnership. And though the topline data proved positive concerns over conditioning agents linger. https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/ https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/"
X Link 2021-06-11T11:53Z 30.9K followers, [--] engagements
"After revealing a flop on its second shot for alpha-1 antitrypsin deficiency Vertex plowed ahead with another data drop from its CRISPR Therapeutics partnership. And though the topline data proved positive concerns over conditioning agents linger. https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/ https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/"
X Link 2021-06-11T20:05Z 30.9K followers, [--] engagements
"After revealing a flop on its second shot for alpha-1 antitrypsin deficiency Vertex plowed ahead with another data drop from its CRISPR Therapeutics partnership. And though the topline data proved positive concerns over conditioning agents linger. https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/ https://endpts.com/vertex-and-crispr-therapeutics-unveil-more-positive-gene-therapy-data-but-busulfan-again-casts-a-shadow-over-the-field/"
X Link 2021-06-13T20:00Z 30.9K followers, [--] engagements
"CRISPR Therapeutics signed a deal with Capsida Biotherapeutics a gene therapy player specializing in AAV engineering to carve out a delivery mechanism for the companys gene editing tech in ALS and the rare neurodegenerative disorder Friedreichs ataxia. https://endpts.com/crispr-therapeutics-takes-a-swing-at-als-gene-editing-in-discovery-deal-with-aav-upstart-capsida/ https://endpts.com/crispr-therapeutics-takes-a-swing-at-als-gene-editing-in-discovery-deal-with-aav-upstart-capsida/"
X Link 2021-06-15T11:43Z 30.9K followers, [--] engagements
"WuXi Biologics Massachusetts manufacturing site isnt even up and running yet and its already getting an upgrade. https://endpts.com/wuxi-biologics-earns-local-nod-for-expansion-to-growing-ma-manufacturing-site/ https://endpts.com/wuxi-biologics-earns-local-nod-for-expansion-to-growing-ma-manufacturing-site/"
X Link 2021-08-26T18:20Z 30.9K followers, [--] engagements
"Bankruptcy judge: $JNJ can spin talc powder into different company potentially slowing plaintiffs' payouts https://endpts.com/bankruptcy-judge-jj-can-spin-talc-powder-into-different-company-potentially-slowing-plaintiffs-payouts/ https://endpts.com/bankruptcy-judge-jj-can-spin-talc-powder-into-different-company-potentially-slowing-plaintiffs-payouts/"
X Link 2021-08-29T00:00Z 31K followers, [--] engagements
"In today's News Briefing: Bluebird bio announced it completed the rolling submission of its BLA to the FDA for betibeglogene autotemcel gene therapy. https://endpts.com/bluebird-sends-blood-disorder-drug-to-fda-for-approval-cg-oncology-enters-collaboration-with-roche-for-tecentriq/ https://endpts.com/bluebird-sends-blood-disorder-drug-to-fda-for-approval-cg-oncology-enters-collaboration-with-roche-for-tecentriq/"
X Link 2021-09-22T14:44Z 30.9K followers, [--] engagements
"In today's #Covid19 roundup: AstraZeneca on Tuesday sought an EUA from the FDA for its long-acting antibody (LAAB) combination treatment which like the Regeneron mAb can be used prophylactically for symptomatic Covid-19. https://endpts.com/covid-19-roundup-astrazeneca-seeks-eua-for-long-acting-antibody-pfizer-vaccine-data-show-strength-against-delta-at-6-months/ https://endpts.com/covid-19-roundup-astrazeneca-seeks-eua-for-long-acting-antibody-pfizer-vaccine-data-show-strength-against-delta-at-6-months/"
X Link 2021-10-05T11:43Z 30.9K followers, [--] engagements
"Driven by innovation from biotech companies including Moderna BioNTech and Regeneron in Covid-19 vaccines and treatments the pharma industry is enjoying unprecedented positive public opinion. https://endpts.com/thanks-for-the-boost-biotech-pharma-industry-reputation-now-close-to-biotech-industry-esteem-harris-poll/ https://endpts.com/thanks-for-the-boost-biotech-pharma-industry-reputation-now-close-to-biotech-industry-esteem-harris-poll/"
X Link 2021-11-07T14:00Z 30.9K followers, [--] engagements
"Three years after Royalty Pharma chief Pablo Legorreta led a group of investors to buy up a pair of biotechs and create a startup called ProKidney the biotech is jumping straight into an $825 million public shell created by SPAC king Chamath Palihapitiya. https://endpts.com/billionaires-chamath-palihapitiya-and-pablo-legorreta-hatch-an-825m-spac-for-cell-therapy-biotech/ https://endpts.com/billionaires-chamath-palihapitiya-and-pablo-legorreta-hatch-an-825m-spac-for-cell-therapy-biotech/"
X Link 2022-01-18T16:10Z 30.9K followers, [--] engagements
"As Novartis CEO Vas Narasimhan figures out exactly what he wants to do with Sandoz the company revealed in its Q4 report that US sales for the generics unit are expected to continue on a downhill slide in the new year. https://endpts.com/vas-narasimhan-reveals-a-disappointing-outlook-for-novartis-generics-unit-while-laying-out-the-pharmas-ma-strategy/ https://endpts.com/vas-narasimhan-reveals-a-disappointing-outlook-for-novartis-generics-unit-while-laying-out-the-pharmas-ma-strategy/"
X Link 2022-02-02T21:00Z 31K followers, [--] engagements
"As Covid-19 has made it more difficult for US regulators to carry out routine inspections WuXi Biologics has been hit with unverified status causing its stock to sink and wipe $9.9 billion off of its market value before trading of its shares was halted. https://endpts.com/wuxi-stock-plummets-wiping-nearly-10b-off-market-value-as-us-adds-it-to-unverified-list/ https://endpts.com/wuxi-stock-plummets-wiping-nearly-10b-off-market-value-as-us-adds-it-to-unverified-list/"
X Link 2022-02-08T17:08Z 31K followers, [--] engagements
"Whatever Voyager is coming up with on its new gene therapy platform Novartis wants a piece of it. https://endpts.com/novartis-takes-a-gamble-on-voyagers-new-aav-tech-inks-1-5b-gene-therapy-discovery-pact/ https://endpts.com/novartis-takes-a-gamble-on-voyagers-new-aav-tech-inks-1-5b-gene-therapy-discovery-pact/"
X Link 2022-03-08T12:30Z 30.9K followers, [--] engagements
"Jumping into the M&A game Regeneron has scooped up a beaten down Checkmate Pharmaceuticals for $250 million in cash bagging its lead drug for melanoma. https://endpts.com/regeneron-buys-art-kriegs-biotech-startup-for-a-discount-price-boosting-i-o-pipeline/ https://endpts.com/regeneron-buys-art-kriegs-biotech-startup-for-a-discount-price-boosting-i-o-pipeline/"
X Link 2022-04-19T12:10Z 31.1K followers, [--] engagements
"WuXi Biologics may be inching closer to working its way off the US unverified list an event that wiped out some $10 billion in market value earlier this year. https://endpts.com/wuxi-biologics-inspection-raises-prospects-for-getting-off-us-unverified-list-report/ https://endpts.com/wuxi-biologics-inspection-raises-prospects-for-getting-off-us-unverified-list-report/"
X Link 2022-07-05T12:06Z 31K followers, [--] engagements
"Biogen filed suit against Sandoz earlier this month accusing the company of attempting to reap the benefits of Biogens hard work and success by allegedly infringing on Tysabris patent rights. https://endpts.com/unsealed-documents-detail-biogens-fight-against-sandoz-tysabri-biosimilar/ https://endpts.com/unsealed-documents-detail-biogens-fight-against-sandoz-tysabri-biosimilar/"
X Link 2022-09-20T21:30Z 30.9K followers, [--] engagements
"Weeks after announcing the spinoff of generics arm Sandoz Vas Narasimhan paints a picture of the new slimmer Novartis with a US-first mindset he said at an investor event on Thursday. https://endpts.com/novartis-unveils-us-first-strategy-ahead-of-sandoz-spinoff/ https://endpts.com/novartis-unveils-us-first-strategy-ahead-of-sandoz-spinoff/"
X Link 2022-09-22T19:22Z 30.9K followers, [--] engagements
"Weeks after announcing the spinoff of generics arm Sandoz Vas Narasimhan paints a picture of the new slimmer Novartis with a US-first mindset he said at an investor event on Thursday. https://endpts.com/novartis-unveils-us-first-strategy-ahead-of-sandoz-spinoff/ https://endpts.com/novartis-unveils-us-first-strategy-ahead-of-sandoz-spinoff/"
X Link 2022-09-24T22:00Z 30.8K followers, [--] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing